



US006291660B1

(12) **United States Patent**
Gaffney et al.

(10) **Patent No.:** **US 6,291,660 B1**
(45) **Date of Patent:** **Sep. 18, 2001**

(54) **FUNGAL GENES REQUIRED FOR NORMAL GROWTH AND DEVELOPMENT**

(75) Inventors: **Thomas Deane Gaffney**, Chapel Hill, NC (US); **Juergen Wendland**, Lörrach (DE); **Fred Dietrich**, Basel; **Peter Philippsen**, Riehen, both of (CH); **Stephen Arthur Goff**, Encinitas, CA (US)

(73) Assignee: **Syngenta Participations AG**, Basel (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/415,522**

(22) Filed: **Oct. 8, 1999**

Related U.S. Application Data

(60) Provisional application No. 60/172,224, filed on Oct. 8, 1998.

(51) **Int. Cl.**⁷ **C07H 21/04**

(52) **U.S. Cl.** **536/23.1**

(58) **Field of Search** 536/23.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,821,090 10/1998 Revuelta Doval et al. .

FOREIGN PATENT DOCUMENTS

0 866 129 A2 9/1998 (EP) .
WO 93/04180 3/1993 (WO) .

OTHER PUBLICATIONS

Whiteway et al. Dominant negative selection of heterologous genes: Isolation of *Candida albicans* genes that interfere with *Saccharomyces cerevisiae* mating factor-induced cell cycle arrest. *PNAS* vol. 89:9410-9414, Nov. 1992.*
Qaife et al. Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. *Biochemistry* vol. 33:7250-7259, Jul. 1994.*
Matsui et al., *Gene*, 114: 43-49 (1992).
Altmann-Johl et al., *Molecular Gene. Genet.* 250: 69-80 (1996).
Madaule et al., *Proc. Natl. Acad. Sci.*, 84: 779-783 (1987).
Bundock et al., *The EMBO Journal* 14(13): 3206-3214 (1995).
Matsui et al. *Mol. Cell Biol.*, 12:5690-9 (1992).
Imai et al., *Genetics*, 142: 359-69 (1996).
Zheng et al., *J. Biol. Chem.*, 268, No. 33: 24629-24634 (1993).
Healy et al., *Mol. Cell Biol.*, 11, No. 11: 5767-5780 (1991).
Bender et al., *Mol. Cell Biol.*, 11, No. 3: 1295-1305 (1991).
Zheng et al., *J. Biol. Chem.*, 269:2369-2372 (1994).
Chan et al., *Genetics*, 135: 677-691 (1993).
Lamarche et al., *Trends Genet.*, 10, No. 12: 436-440 (1994).
Stevenson et al., *Genes Dev.*, 9: 2949-2963 (1995).
Gibson et al., *Trends Biochem. Sci.*, 19:349-353 (1994).
Chant et al., *Cell* 65: 1203-1212 (1991).

Chant et al., *J. Cell Biol.*, 129: 767-78 (1995).
Sanders et al., *Curr. Biol.*, 5, No. 11: 1213-1215 (1995).
Yang et al., *J. Cell Biol.*, 136, No. 1: 111-123 (1997).
Dorer et al., *Genetics*, 146: 39-55 (1997).
Ohya et al., *Mol. Biol. Cell*, 4: 1017-1025 (1993).
Yamochi et al., *J. Cell Biol.*, 25, No. 5: 1077-1093 (1994).
Qadota et al., *Proc. Natl. Acad. Sci. USA*, 91: 9317-9321 (1994).
Cid et al., *Microbiology*, 144: 25-36 (1998).
Cid et al., *Microbiol. Rev.*, 59: 345-386 (1995).
Qadota et al., *Science*, 272:279-281 (1996).
Drgonova et al., *Science* 272: 277-279 (1996).
Kamada et al., *J. Biol. Chem.*, 271, No. 16: 9193-9196 (1996).
Ozaki et al., *EMBO J.*, 15, No. 9: 2196-2207 (1996).
Mazur et al., *J. Biol. Chem.*, 271, No. 24: 14604-9 (1996).
Chen et al., *Mol. Cell Biol.* 16: 1376-1390 (1996).
Clemens et al., *Mol. Cell Biol.*, 16, No. 9: 4656-4664 (1996).
Nonaka et al., *EMBO J.*, 14, No. 23: 5931-5938 (1995).
Schmidt et al., *Cell*, 88: 531-542 (1997).
Imamura et al., *EMBO J.*, 16, No. 10: 2745-2755 (1997).
Sasamura et al., *Mol. Gen. Genet.*, 254: 486-494 (1997).
Kondoh et al., *J. Bacteriol.*, 179, No. 24: 7734-7741 (1997).
Alberts et al., *J. Biol. Chem.*, 273, No. 15:8616-8622 (1998).
Bickle et al., *EMBO J.*, No. 8:2235-2245 (1998).
Fujiwara et al., *Mol. Biol. Chem.*, 9: 1221-1233 (1998).
Chen et al., *Genes & Development*, 11:2958-2971 (1997).
Hermann et al., *The Journal of Cell Biology*, 137, No. 1: 141-153 (1997).
Hong et al., *Molecular and Cellular Biology*, 14, No. 2: 1017-1025 (1994).
Kim et al., *The Journal of Cell Biology*, 127, No. 5: 1381-1394 (1994).
Peterson et al., *The Journal of Cell Biology*, 127, No. 5: 1395-1406 (1994).
Smith et al., *Science*, 274: 2069-2074 (1996).
Wang et al., *Genetics*, 147: 1595-1607 (1997).
Wang et al., *Molecular Biology of the Cell*, 6: 1011-1024 (1995).

* cited by examiner

Primary Examiner—Terry McKelvey
Assistant Examiner—William Sandals
(74) *Attorney, Agent, or Firm*—Bruce Vrana

(57) **ABSTRACT**

The present invention relates to genomic DNA sequences obtained from terminal sequencing of random genomic fragments of the filamentous fungus *Ashbya gossypii*, to the sequences obtained therewith and the use of the sequences for forensic identification, to characterize genes and gene organization or this ascomycete by inter-genomic comparison, to identify biosynthetic genes that can be used as selection markers, to isolate promoters and terminators for application in a homologous as well as heterologous context, to find putative centromere containing clones, chromosome mapping, chromosome identifying, general information about chromosome organization and in addition to identify ORF containing SRS sequences with no homology to *S. cerevisiae* or any other organism which allows the identification of *A. gossypii* specific genes.

6 Claims, No Drawings

FUNGAL GENES REQUIRED FOR NORMAL GROWTH AND DEVELOPMENT

This application claims the benefit of U.S. Provisional Application No. 60/172,224, filed Oct. 8, 1998. The disclosure of this priority document is hereby expressly incorporated by reference in its entirety into the instant disclosure.

FIELD OF THE INVENTION

The invention relates to nucleic acid sequences isolated from *Ashbya gossypii* that encode proteins essential for fungal growth. The invention also includes the methods of using these proteins pesticide targets, particularly fungicide targets, based on the essentiality of the gene for normal growth and development. The invention is also useful as a screening assay to identify inhibitors that are potential pesticides, particularly fungicides.

BACKGROUND OF THE INVENTION

The phytopathogenic fungus *Ashbya gossypii* is a filamentously growing ascomycete that was first isolated as a plant pathogen in tropical and sub-tropical regions. It infects the seed capsule of cotton plants and has also been isolated from tomatoes and citrus fruits. The infection of the seed capsule is caused by transmission of *A. gossypii* mycelium pieces or spores by stinging-sucking insects and causes a disease called stigmatomycosis. Presently, *A. gossypii* represents the most compact eukaryotic genome, compared to genome sizes of 12.5 Mb for *S. cerevisiae* (Chu et al., 1986), 31.0 Mb for *Aspergillus nidulans* (Brody and Carbon, 1989) and 47.0 Mb for *Neurospora crassa* (Orbach et al., 1988).

A. gossypii is systematically grouped to the endomycetales belonging to the family of spermothoraceae. This classification is based on the observation that the spores that develop in hyphal compartments called sporangia look like ascospores, which are defined as endproducts of meiosis.

Since *Ashbya gossypii* is a filamentous ascomycete, and is capable of growing only by filamentous (hyphal) growth, fungal targets found in this model organism are predictive of targets which will be found in other pathogens, the vast majority of which grow in a filamentous fashion.

SUMMARY OF THE INVENTION

It is an object of the invention to provide an effective and beneficial method to identify novel pesticides, particularly fungicides. A feature of the invention is the identification of genes having a putative activity based on their homology to yeast genes. Genes of the invention comprise a putative GTP binding protein genes (herein referred to as AG001 and AG002 genes), putative GTPase activating protein genes (AG003 and AG004), putative phosphatidylinositol-4 kinase protein gene (AG005) and putative cytokinesis gene (AG006). Another feature of the invention is the discovery that the genes of the invention, AG001 (SEQ ID. NO: 1), AG002 (SEQ Id. NO 3), AG003 (SEQ ID. NO: 5), AG004 (SEQ ID. NO: 7), AG005 (SEQ Id. NO: 9) and AG006 (SEQ ID. NO: 11) are essential for fungal growth and development. An advantage of the present invention is that the newly discovered essential genes containing a novel fungicidal mode of action enables one skilled in the art to easily and rapidly identify novel fungicides.

One object of the present invention is to provide essential genes in fungi for assay development to detect inhibitory compounds with pesticidal, particularly fungicidal activity. Genetic results show that when AG001, AG002, AG003,

AG004, AG005 and AG006 are mutated in *Ashbya gossypii*, the resulting phenotype is at best suppressed growth and at worst lethal. Suppressed growth as used herein results in a growth rate of half the growth rate observed in wild type or lower where 10% that of the wild-type growth rate was observed or no growth was macroscopically detected at all. Applicants further observed that when AG001, AG002, AG003, AG004, AG005 and AG006 are mutated in *Ashbya gossypii* abnormal filament development was observed. This suggests a critical role for the gene products encoded by the mutated genes.

The inventors of the present invention have demonstrated that the gene products of the invention are essential in *Ashbya gossypii*. This implies that chemicals which inhibit the function of the protein in fungi, particularly, filamentous fungi, are likely to have detrimental effects on fungi and are potentially good fungicide candidates. The present invention therefore provides methods of using a purified protein encoded by the gene sequence described below to identify inhibitors thereof, which can then be used as fungicides to suppress the growth of pathogenic fungi.

Pathogenic fungi is defined as those capable of colonizing a host and causing disease. Examples of fungal pathogens include plant pathogens such as *Septoria tritici*, *Stagnospora nodorum*, *Botrytis cinerea*, *Fusarium graminearum*, *Magnaporthe grisea*, *Cochliobolus heterostrophus*, *Colletotrichum heterostrophus*, *Ustilago maydis*, *Erysiphe graminis*, plant pathogenic oomycetes such as *Pythium ultimum* and *Phytophthora infestans*, and human pathogens such as *Candida albicans* and *Aspergillus fumigatus*.

The present invention discloses novel nucleotide sequences derived from *Ashbya gossypii* designated as the AG001 gene, the AG002 gene, the AG003 gene, the AG004 gene, the AG005 gene and the AG006 gene. The nucleotide sequence of the genomic clones are set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11 respectively. The amino acid sequence encoded by the above sequences are set forth in SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, SEQ ID NO:10 or SEQ ID NO:12. The present invention also includes nucleotide sequences substantially similar to those set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 OR SEQ ID NO: 11 and amino acid sequences substantially similar to those set out in SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, SEQ ID NO:10 or SEQ ID NO:12.

The present invention also encompasses fungal proteins whose amino acid sequence are substantially similar to the amino acid sequences set forth in SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, SEQ ID NO:10 or SEQ ID NO:12. In a particular embodiment, the present invention encompasses nucleic acid sequences and amino acid sequences of filamentous fungi. The present invention also includes methods of using the AG001 to AG006 gene products as fungicide targets, based on the essentiality of the genes for normal growth and development. Normal growth and development is defined as a growth rate substantially similar to that observed in wild type fungus, preferably greater than at least 50% the growth rate observed in wild type fungus and particularly greater than 10% the growth rate observed in wild type fungus. Normal growth and development may also be defined, when used in relation to filamentous fungi, as normal filament development development (including normal septation and normal nuclear migration and distribution), normal sporulation, and normal production of any infection structures (e.g. appressoria). Conversely suppressed or inhibited growth as used herein is

defined as less than half the growth rate observed in wild type or lower where 10% that of the wild-type growth rate was observed or no growth was macroscopically detected at all or abnormal filament development.

Furthermore, the invention can be used in screening assays to identify inhibitors that are potential pesticides, particularly fungicides. Encompassed by the present invention is the use of sequences selected from the attached Sequence Listing to identify substances having antifungal activity; the use of sequences selected from the attached Sequence Listing to identify substances having pesticidal, particularly fungicidal, activity.

Further comprised is the use of an a DNA sequence selected from the Sequence Listing and variants thereof in a screening method for identifying compounds capable of inducing broad spectrum disease resistance in plants.

In a further embodiment according to the invention, a DNA sequence selected from the Sequence Listing may also be used for distinguishing among different species of plant pathogenic fungi and for distinguishing fungal pathogens from other pathogens such as bacteria. In another preferred embodiment, the present invention describes a method for identifying chemicals having the ability to inhibit any one or more of AG001, AG002, AG003, AG004, AG005 and AG006 activity in fungi preferably comprising the steps of: a) obtaining transgenic fungus and/or fungal cell, preferably stably transformed, comprising a non-native nucleotide sequence or an endogenous nucleotide sequences operably linked to non-native promoter, preferably an inducible promoter, encoding an enzyme having and activity and capable of overexpressing an enzymatically active AG001, AG002, AG003, AG004, AG005 or AG006 gene product where overexpression of the gene product is suppresses or inhibits the normal growth and development of the fungus; b) applying a compound to the transgenic fungus and/or fungal cell c) determining the growth and/or development of the transgenic fungus and/or fungal cell after application of the compound; d) comparing the growth and/or development of the transgenic fungus and/or fungal cell after application of the chemical to the growth and/or development of the corresponding transgenic fungus and/or fungal cell to which the compound was not applied; and e) selecting compound that does not results in reduction of the suppressed or inhibited growth and/or development in the transgenic fungus and/or fungal cell in comparison to the untreated transgenic fungus and/or fungal cell.

In a preferred embodiment, the proteins having AG001, AG002, AG003, AG004, AG005 or AG006 activities are encoded by nucleotide sequence derived from fungi, preferably filamentous fungi, particularly from *Ashbya gossypii*, desirably identical or substantially similar to the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO: 7, SEQ ID NO:9 or SEQ ID NO:11. In another embodiment, the proteins having AG001, AG002, AG003, AG004, AG005 or AG006 activity are encoded by nucleotide sequences capable of encoding the amino acid sequences of: SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, SEQ ID NO:10 or SEQ ID NO:12. In yet another embodiment, the proteins having AG001, AG002, AG003, AG004, AG005 or AG006 activity have amino acid sequences identical or substantially similar to the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8, SEQ ID NO:10 or SEQ ID NO:12 respectively.

The invention also provides a method for suppressing the growth of a fungus comprising the step of applying to the

fungus a compound that inhibits the naturally occurring AG001, AG002, AG003, AG004, AG005 and/or AG006 activity in the fungus.

Other objects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

Definitions

For clarity, certain terms used in the specification are defined and presented as follows:

Co-factor: natural reactant, such as an organic molecule or a metal ion, required in an enzyme-catalyzed reaction. A co-factor is e.g. NAD(P), riboflavin (including FAD and FMN), folate, molybdopterin, thiamin, biotin, lipoic acid, pantothenic acid and coenzyme A, S-adenosylmethionine, pyridoxal phosphate, ubiquinone, menaquinone. Optionally, a co-factor can be regenerated and reused.

Enzyme activity: means herein the ability of an enzyme to catalyze the conversion of a substrate into a product. A substrate for the enzyme comprises the natural substrate of the enzyme but also comprises analogues of the natural substrate which can also be converted by the enzyme into a product or into an analogue of a product. The activity of the enzyme is measured for example by determining the amount of product in the reaction after a certain period of time, or by determining the amount of substrate remaining in the reaction mixture after a certain period of time. The activity of the enzyme is also measured by determining the amount of an unused co-factor of the reaction remaining in the reaction mixture after a certain period of time or by determining the amount of used co-factor in the reaction mixture after a certain period of time. The activity of the enzyme is also measured by determining the amount of a donor of free energy or energy-rich molecule (e.g. ATP, phosphoenolpyruvate, acetyl phosphate or phosphocreatine) remaining in the reaction mixture after a certain period of time or by determining the amount of a used donor of free energy or energy-rich molecule (e.g. ADP, pyruvate, acetate or creatine) in the reaction mixture after a certain period of time.

Heterologous DNA Sequence: a DNA sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring DNA sequence.

Homologous DNA Sequence: a DNA sequence naturally associated with a host cell into which it is introduced.

Isogenic: plants which are genetically identical, except that they may differ by the presence or absence of a transgene.

Isolated: in the context of the present invention, an isolated DNA molecule or an isolated enzyme is a DNA molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated DNA molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell.

Mature protein: protein which is normally targeted to a cellular organelle, such as a chloroplast, and from which the transit peptide has been removed.

Minimal Promoter: promoter elements, particularly a TATA element, that are inactive or that have greatly reduced promoter activity in the absence of upstream activation. In the presence of a suitable transcription factor, the minimal promoter functions to permit transcription.

Modified Enzyme Activity: enzyme activity different from that which naturally occurs in a plant (i.e. enzyme activity that occurs naturally in the absence of direct or

indirect manipulation of such activity by man), which is tolerant to inhibitors that inhibit the naturally occurring enzyme activity.

Significant Increase: an increase in enzymatic activity that is larger than the margin of error inherent in the measurement technique, preferably an increase by about 2-fold or greater of the activity of the wild-type enzyme in the presence of the inhibitor, more preferably an increase by about 5-fold or greater, and most preferably an increase by about 10-fold or greater.

Significantly less: means that the amount of a product of an enzymatic reaction is larger than the margin of error inherent in the measurement technique, preferably a decrease by about 2-fold or greater of the activity of the wild-type enzyme in the absence of the inhibitor, more preferably a decrease by about 5-fold or greater, and most preferably a decrease by about 10-fold or greater.

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The term "substantially similar" is specifically intended to include nucleotide sequences wherein the sequence has been modified to optimize expression in particular cells. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence desirably is at least 65%, more desirably at least 75%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, yet still more preferably at least 99%. Sequence comparisons are carried out using a Smith-Waterman sequence alignment algorithm (see e.g. Waterman, M.S. Introduction to Computational Biology: Maps, sequences and genomes. Chapman & Hall. London: 1995. ISBN 0-412-99391-0). The localS program, version 1.16, is used with following parameters: match: 1, mismatch penalty: 0.33, open-gap penalty: 2, extended-gap penalty: 2. A nucleotide sequence "substantially similar" to reference nucleotide sequence hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50° C. with washing in 2×SSC, 0.1% SDS at 50° C., more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50° C. with washing in 1×SSC, 0.1% SDS at 50° C., more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50° C. with washing in 0.5×SSC, 0.1% SDS at 50° C., preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50° C. with washing in 0.1×SSC, 0.1% SDS at 50° C., more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50° C. with washing in 0.1×SSC, 0.1% SDS at 65° C.

The term "substantially similar", when used herein with respect to a protein, means a protein corresponding to a reference protein, wherein the protein has substantially the same structure and function as the reference protein, e.g. where only changes in amino acids sequence not affecting the polypeptide function occur. When used for a protein or an amino acid sequence the percentage of identity between the substantially similar and the reference protein or amino acid sequence desirably is at least 52%, more desirably 65%, more desirably at least 75%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, yet still more preferably at least 99%.

Substrate: a substrate is the molecule that the enzyme naturally recognizes and converts to a product in the biochemical pathway in which the enzyme naturally carries out its function, or is a modified version of the molecule, which is also recognized by the enzyme and is converted by the enzyme to a product in an enzymatic reaction similar to the naturally-occurring reaction.

Tolerance: the ability to continue normal growth or function when exposed to an inhibitor or herbicide in an amount sufficient to suppress the normal growth or function of native, unmodified plants.

Transformation: a process for introducing heterologous DNA into a cell, tissue, or plant. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof.

Transgenic: stably transformed with a recombinant DNA molecule that preferably comprises a suitable promoter operatively linked to a DNA sequence of interest.

BRIEF DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 comprises a AG001 coding region
 SEQ ID NO:2 comprises an amino acid sequence encoded by the coding region of SEQ ID NO:1
 SEQ ID NO:3 comprises a AG002 coding region.
 SEQ ID NO:4 comprises an amino acid sequence encoded by the coding region of SEQ ID NO:3.
 SEQ ID NO:5 comprises a AG003 coding region.
 SEQ ID NO:6 comprises an amino acid sequence encoded by the coding region of SEQ ID NO:5.
 SEQ ID NO:7 comprises a AG004 coding region.
 SEQ ID NO:8 comprises an amino acid sequence encoded by the coding region of SEQ ID NO:7.
 SEQ ID NO:9 comprises a AG005 coding region.
 SEQ ID NO:10 comprises an amino acid sequence encoded by coding region of SEQ ID NO:9.
 SEQ ID NO:11 comprises a AG006 coding region.
 SEQ ID NO:12 comprises an amino acid sequence encoded by coding region of SEQ ID NO:11.

DETAILED DESCRIPTION OF THE INVENTION

Essentiality of the AG001, AG002, AG003, AG004, AG005 and AG006 Genes in *Ashbya gossypii* Demonstrated by Gene Disruption

Owing to the provision within the scope of this invention of a novel and powerful gene disruption process, there is no longer a need to know the exact biological function of the protein product encoded by a gene comprising one of the *A. gossypii* DNA sequences provided herein. As shown in the examples below, the identification of novel gene structures, as well as the essentiality of the AG001, AG002, AG003, AG004, AG005 and AG006 genes for normal growth and development, have been demonstrated for the first time in *Ashbya gossypii* using gene disruption techniques. Having established the essentiality of AG001, AG002, AG003, AG004, AG005 and AG006 function in fungi and having identified the nucleic acid sequences encoding these essential activities, the inventors thereby provide an important and sought after tool for new pesticide, particularly fungicide, development.

Recombinant Production of and Uses Thereof

For recombinant production of AG001, AG002, AG003, AG004, AG005 and AG006 in a host organism, a nucleotide sequence encoding AG001, AG002, AG003, AG004, AG005 or AG006 protein is inserted into an expression cassette

designed for the chosen host and introduced into the host where it is recombinantly produced. The choice of specific regulatory sequences such as promoter, signal sequence, 5' and 3' untranslated sequences, and enhancer appropriate for the chosen host is within the level of skill of the routinier in the art. The resultant molecule, containing the individual elements operably linked in proper reading frame, may be inserted into a vector capable of being transformed into the host cell. Suitable expression vectors and methods for recombinant production of proteins are well known for host organisms such as *E. coli*, yeast, and insect cells (see, e.g., Luckow and Summers, Bio/Technol. 6: 47 (1988), and baculovirus expression vectors, e.g., those derived from the genome of Autographa californica nuclear polyhedrosis virus (AcMNPV). A preferred baculovirus/insect system is pAcHLT (Pharmingen, San Diego, Calif.) used to transfect *Spodoptera frugiperda* Sf9 cells (ATCC) in the presence of linear Autographa californica baculovirus DNA (Pharmingen, San Diego, Calif.). The resulting virus is used to infect HighFive *Tricoplusia ni* cells (Invitrogen, La Jolla, Calif.). Further preferred expression systems are commercially available such as Baculovirus expression systems: MaxBac 2.0 kit; Invitrogen, Calsbad, Calif.; BACPAK™ Baculovirus Expression System; CLONTECH™, Palo Alto, Calif.; for Yeast expression vectors: pYEUra3; CLONTECH™, Palo Alto, Calif.; EASYSELECT™ Pichia expression kit; Invitrogen, Calsbad, Calif.; ESP Yeast Protein Expression and Purification System; Stratagene, La Jolla, Calif.; *E. coli* expression vectors: pKK233-2; CLONTECH™, Palo Alto, Calif.; pET3 series vectors; Stratagene, La Jolla, Calif.

In a preferred embodiment, the nucleotide sequence encoding a protein having AG001, AG002, AG003, AG004, AG005 Or AG006 activity is derived from an eukaryote, such as a mammal, a fly or a yeast, but is preferably derived from a fungus, particularly a filamentous fungus. In a further preferred embodiment, the nucleotide sequence is identical or substantially similar to the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11, or encodes a protein having AG001, AG002, AG003, AG004, AG005 or AG006 activity, whose amino acid sequence is identical or substantially similar to the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12 respectively. The nucleotide sequences set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 OR SEQ ID NO: 11 encode the protein comprising amino acid sequence is set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 OR SEQ ID NO: 12. In another preferred embodiment, the nucleotide sequence is derived from a prokaryote, preferably a bacteria.

Recombinantly produced AG001, AG002, AG003, AG004, AG005, or AG006 is isolated and purified using a variety of standard techniques. The actual techniques that may be used will vary depending upon the host organism used, whether the protein is designed for secretion, and other such factors familiar to the skilled artisan (see, e.g. chapter 16 of Ausubel, F. et al., "Current Protocols in Molecular Biology", pub. by John Wiley & Sons, Inc. (1994). Assays for Characterizing the AG001, AG002, AG003, AG004, AG005 and AG006 Proteins

Recombinantly produced AG001, AG002, AG003, AG004, AG005 and AG006 proteins are useful for a variety of purposes. For example, they can be used in in vitro assays to screen known pesticidal, particularly fungicidal chemicals whose target has not been identified to determine if they inhibit AG001, AG002, AG003, AG004, AG005 or AG6.

Such in vitro assays may also be used as more general screens to identify chemicals that inhibit such enzymatic activities and that are therefore novel pesticide, particularly fungicide, candidates. Alternatively, recombinantly produced AG001, AG002, AG003, AG004, AG005 or AG006 proteins may be used to elucidate the complex structure of these molecules and to further characterize their association with known inhibitors in order to rationally design new inhibitory pesticides, particularly fungicides. Nucleotide sequences substantially similar to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 OR SEQ ID NO: 11 and proteins substantially similar to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 OR SEQ ID NO: 12 from any source, including microbial sources, can be used in the assays exemplified herein. Desirably such nucleotide sequences and proteins are derived from fungi. More desirably, they are derived from filamentous fungi, particularly *Ashbya gossypii*. Alternatively, such nucleotide sequences and proteins are derived from non-yeast sources, alternatively from non-*Saccharomyces cerevisiae* sources.

A simple assay can be developed to screen for compounds that affect normal functioning of the fungal-encoded activity. Such compounds are promising in vitro leads that can be tested for in vivo pesticidal, particularly fungicidal, activity. A nucleic acid sequence of the invention according to any one of the sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 OR SEQ ID NO: 11 may be operably linked to a strong inducible promoter, such promoters being known in the art. The vector comprising the selected gene of the invention operably linked to the selected inducible promoter may be transformed into bacteria, such as *E. coli*. Transformed *E. coli* harboring and functionally overexpressing expressing a AG001, AG002, AG003, AG004, AG005 or AG006 gene may be grown in a 96-well form automated high-throughput screening where inducible over expression of the selected gene is lethal or suppresses growth of the host. Compounds that are effective in blocking function of the AG001, AG002, AG003, AG004, AG005 or AG006 protein results in bacterial growth. This growth is measured by simple turbidometric means.

In another embodiment, an assay for inhibitors of the AG001, AG002, AG003, AG004, AG005 or AG006 activities uses transgenic fungi or fungal cells capable of overexpressing a nucleotide sequence having AG001, AG002, AG003, AG004, AG005 or AG006 activity respectively operably linked to a strong inducible promoter e.g., wherein the selected gene product is enzymatically active in the transgenic fungi and/or fungal cells and inducible overexpression of the gene inhibits and/or suppresses growth and/or development of the fungus. The nucleotide sequence is preferably derived from an eukaryote, such as a yeast, but is preferably derived from a fungus and more particularly from a filamentous fungus. In a further preferred embodiment, the nucleic acid sequences set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 OR SEQ ID NO: 11 SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 OR SEQ ID NO: 11 encode enzymes having AG001, AG002, AG003, AG004, AG005 or AG006 activity respectively, whose amino acid sequence is identical or substantially similar to the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 OR SEQ ID NO: 12. The transgenic fungus or fungal cells are grown in 96-well format microtiter dishes for high-throughput screening. Compounds that are effective in blocking function of the AG001, AG002, AG003, AG004,

AG005 or AG006 protein results in fungal growth. This growth is measured by methods known in the art. In a particular embodiment the transgenic fungus is *Ashbya gossypii*.

Similar assays based on expression of the fungal genes of the invention in yeast, using appropriate expression systems as described above may also be used.

In Vitro Inhibitor Assays: Discovery of Small Molecule Ligand that Interacts with Protein of Unknown Function

Novel technologies are being examined that can detect interactions between a protein and a ligand without knowing the biological function of the protein. A short description of three methods is presented, including fluorescence correlation spectroscopy, surface-enhanced laser desorption/ionization, and biacore technologies. Many more of these methods are currently being discovered, and some may be amenable to automated, large scale screening in light of this disclosure.

Fluorescence Correlation Spectroscopy (FCS) theory was developed in 1972 but it is only in recent years that the technology to perform FCS became available (Madge et al. (1972) Phys. Rev. Lett., 29: 705-708; Maiti et al. (1997) Proc. Natl. Acad. Sci. USA, 94: 11753-11757). FCS measures the average diffusion rate of a fluorescent molecule within a small sample volume. The sample size can be as low as 103 fluorescent molecules and the sample volume as low as a the cytoplasm of a single bacterium. The diffusion rate is a function of the mass of the molecule and decreases as the mass increases. FCS can therefore be applied to protein-ligand interaction analysis by measuring the change in mass and therefore in diffusion rate of a molecule upon binding.

Surface-Enhanced Laser Desorption/Ionization (SELDI) was invented by Hutchens and Yip during the late 1980's (Hutchens and Yip (1993) Rapid Commun. Mass Spectrom. 7: 576-580). When coupled to a time-of-flight mass spectrometer (TOF), SELDI provides a mean to rapidly analyze molecules retained on a chip. It can be applied to ligand-protein interaction analysis by covalently binding the target protein on the chip and analyze by MS the small molecules retained by this protein (Worrall et al. (1998) Anal. Biochem. 70: 750-756). Biacore relies on changes in the refractive index at the surface layer upon binding of a ligand to a protein immobilized on the layer. In this system, a collection of small ligands is injected sequentially in a 2-5 ul cell with the immobilized protein. Binding is detected by surface plasmon resonance (SPR) by recording laser light refracting from the surface. In general, the refractive index change for a given change of mass concentration at the surface layer, is practically the same for all proteins and peptides, allowing a single method to be applicable for any protein (Liedberg et al. (1983) Sensors Actuators 4: 299-304; Malmquist (1993) Nature, 361: 186-187).

IV. In Vivo Inhibitor Assay

In one embodiment, a suspected pesticide, particularly fungicide, for example identified by in vitro screening, is applied to fungi at various concentrations. After application of the suspected fungicide, its effect on the fungus, for example inhibition or suppression of growth and development is recorded.

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

EXAMPLES

Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described

by Sambrook, et al., Molecular Cloning, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and by T. J. Silhavy, M. L. Berman, and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1984) and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987),

Construction and characterization of a Genomic Library of *A. gossypii* (strain ATCC10895), identification of ORF and promoters is described in U.S. patent application Ser. No: 08/998,416 which is hereby incorporated by reference in its entirety.

Example 1

15 Identification of Antifungal Drug Targets Represented in the Sequence Listing

Gene disruptions of *Ashbya gossypii* genes are generated by a method using short flanking homology regions to produce gene targeting events. The short flanking homology regions are included within polymerase chain reaction primers of 65 nucleotide overall sequence length. Each of these 65-mers contains approximately 45 nucleotides homology to the target gene locus the target gene locus being identified as described in U.S. patent application Ser. No. 08/998,416 now U.S. Pat. No. 6,239,264 incorporated above by reference, and 20 nucleotides homology (invariant) to a geneticin resistance gene module (also described in U.S. patent application Ser. No. 08/998,416 now U.S. Pat. No. 6,239,264 previously incorporated by reference), with one primer (designated S1) anchored to the 5' end of the geneticin resistance module (using the invariant sequence 5'-GCTAGGGATAACAGGGTAAT-3') (SEQ ID NO:13) and the other primer of the pair (designated S2) anchored to the 3' end of the geneticin resistance module (using the invariant sequence 5'-AGGCATGCAAGCTTAGATCT-3') (SEQ ID NO:14). The PCR product resulting from the amplification of the geneticin resistance module with such an S1/S2 primer pair thus consists of the module flanked by short flanking homology regions of ca. 45 nucleotides specific to the chosen gene disruption site.

Once an S1/S2 primer pair is designed for a particular gene target, approximately 10 ug of the desired geneticin resistance module is obtained by linearizing a vector containing the geneticin resistance gene positioned behind the an appropriate fungal promoter (for example, the *Saccharomyces cerevisiae* TEF1 promoter) and subjecting the linearized template to approximately 35 rounds of a PCR reaction consisting of the following steps: Step 1: Denaturation at 96C. for 30 seconds; Step 2: Primer annealing at 50 C for 30 seconds; Step 3: Elongation reaction at 72 C. for 2.5 minutes. Following the 35th round of this protocol, a final elongation period of 5 minutes at 72 C. is carried out.

Transformation of the PCR product resulting from amplification with the S1/S2 primer pair is done by electroporation as follows: 1) Inoculate 100 ml of AFM media (1% casein peptone, 2% glucose, 1% yeast extract, 0.1% myo-inositol) with an *Ashbya* spore suspension of approximately 10^7 spores. 2) Incubate at 30 C. for a maximum of 18 hours at a shaker speed of 200 rpm. 3) Collect the resultant fungal mycelia by filtration and wash once with sterile water. 4) Resuspend 1 gram of mycelia (wet weight) in 40 ml of 50 mM potassium phosphate buffer, pH 7.5 containing 25 mM DTT and incubate at 30 C. for 30 minutes with gentle shaking. 5) Collect the mycelia by filtration and wash once with 50 ml of cold STM buffer (275 mM sucrose, 10 mM Tris-HCl, pH 7.5, 2 mM MgCl₂). 6) Resuspend the mycelia to a dense mixture in STM buffer. 7) Mix approximately 150

ul of the mycelial mixture with 10 ug of PCR product (in a maximum volume of 50 ul) in an Eppendorf tube and transfer the mixture to an electroporation cuvette with a 4 mM gap distance. 8) Apply an electric field pulse of 1.5 kV, 100 ohms, 25 uF which will result in a pulse length of approximately 2.3 milliseconds. Add 1 ml of AFM media to the cuvette and spread equal amounts onto 3 pre-dried AFM agar plates. 9) Incubate plates for a minimum of 4 hours at 30 C. 10) Overlay the plates with 8 ml of a 0.5% agarose toplayer containing Geneticin/G418 at a final concentration of 200 ug/ml. 11) Incubate at 30 C. for approximately 3 days to allow sufficient growth of geneticin resistant transformants.

Verification of the desired transformation event resulting in homologous integration of the geneticin resistance module in the target of interest is achieved by PCR using verification primers designated G1 (positioned upstream of the S1 region) and G4 (positioned downstream of the S2 region) and template DNA purified from putative *Ashbya* transformants. Additional verification primers designated G2 (5'-GTTTAGTCTGACCATCTCATCTG-3') (SEQ ID NO:15) and G3 (5'-TCGCAGACCGATAACCAGGATC-3') (SEQ ID NO:16) are derived from the open reading frame of the selectable geneticin resistance gene such that the detection of a G1/G2 PCR product and or a G3/G4 PCR product of a predictable size serves to verify the desired gene disruption event. Also, verification of the desired gene disruption can be determined by standard DNA hybridization experiments.

Determination of whether a gene is essential to growth of *Ashbya* can be achieved by the following analysis. The transformation of DNA fragments described above utilizes multinucleate *Ashbya mycelia* as recipients. Therefore a primary transformant able to grow on geneticin containing media originates as a mycelium containing cells at least one of which has at least one transformed nucleus, but usually containing non-transformed nuclei as well. Thus, if an essential gene is disrupted in the transformed nucleus, the essential gene product can, in many instances, still be supplied by the non-transformed nuclei within the same cell. Such primary transformants usually exhibit normal growth and sporulation, and spores are collected from primary transformants allowed to grow at 30 C. for at least 5 days. Since spores are uninucleate, however, transformants which have an essential gene disrupted in nuclei containing the geneticin resistance cartridge will fail to yield spores which grow normally, if at all, on geneticin-containing media.

S1 and S2 primer pairs usable to generate disruptions of the indicated genes are as follows:

AG001: S1:
5'-AGGACCACTAGCTCGTTGCGCTGCAATATAATA
ATAAGAACGAGA GCTAGGGATAACAGGGTAAT-3'
(SEQ ID NO:17)
S2:
5'-AAGTATTCAATCAACTATGTGAGTAGTTTCTT
GTAGGCAGTCTCC
AGGCATGCAAGCTTAGATCT-3'(SEQ ID NO:18)
AG002: S1:
5'-CTGGCATCAGAGGAAGCTCCCACCACCAAGCT
CTACAAACACAAG GCTAGGGATAACAGGGTAAT-
3'(SEQ ID NO:19)
S2:
5'-ATTATATTAGTATAGTCTAAAGTTGCAGGCAG
TGGGTATTAAGT
AGGCATGCAAGCTTAGATCT-3'(SEQ ID NO:20)
AG003: S1:
5'-ACTTGCCTACTCTTTCGCGTGCTCGTCAGCCAC
CGAACAACGCAG GCTAGGGATAACAGGGTAAT-3'
(SEQ ID NO:21)
S2:
5'-TTAAAGAATGATAAAGAACCAAAAACACCA
CGAGCTTG CATAACA
AGGCATGCAAGCTTAGATCT-3'(SEQ ID NO:22)
AG004: S1:
5'-GTGCGTGTCAGCGAGCATCTAATCAAGCTGCA
AGGCGCCGGAAAT GCTAGGGATAACAGGGTAAT-
3'(SEQ ID NO:23)
S2:
5'-TTATCACATATTTCTAAGTTAATAGATATTTTT
ACTTAGTATGAA AGGCATGCAAGCTTAGATCT-
3'(SEQ ID NO:24)
AG006: S1:
5'-GAGAGAGACGCTACGGTACTACGAATTTCTCT
GTAGAGTTGGAGA GCTAGGGATAACAGGGTAAT-
3'(SEQ ID NO:25)
S2: 5'-TACTATTGAGAATGTTTCGCGACTGCATGTAA
AGTCTCAAAAACCTT
AGGCATGCAAGCTTAGATCT-3'(SEQ ID NO:26)
AG005: S1:
5'-AAATATAATAAAAATTGACAACTGGCTAGAAGT
GATACCGCAGTT GCTAGGGATAACAGGGTAAT-3'
(SEQ ID NO:27)
S2:
5'-CCTCTTATAGTTCATGACCCATTCATATGCGT
CATTCAGGTCTCT
AGGCATGCAAGCTTAGATCT-3'(SEQ ID NO:28)

The above disclosed embodiments are illustrative. This disclosure of the invention will place one skilled in the art in possession of many variations of the invention. All such obvious and foreseeable variations are intended to be encompassed by the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 28

<210> SEQ ID NO 1

<211> LENGTH: 624

<212> TYPE: DNA

<213> ORGANISM: *Ashbya gossypii*

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(624)

<400> SEQUENCE: 1

-continued

```

atg tct cag caa atg cat aac ccc agt atc agg aga aaa ttg gtg atc      48
Met Ser Gln Gln Met His Asn Pro Ser Ile Arg Arg Lys Leu Val Ile
  1             5             10             15

gtc gga gat ggt gca tgc ggg aaa aca tgt ctt ttg att gtg ttt gcc      96
Val Gly Asp Gly Ala Cys Gly Lys Thr Cys Leu Leu Ile Val Phe Ala
             20             25             30

aag gga aag ttc cca cag gtg tat gtt cct acg gtt ttc gac aac tac      144
Lys Gly Lys Phe Pro Gln Val Tyr Val Pro Thr Val Phe Asp Asn Tyr
             35             40             45

gtt gca gat gtg gag gta gac ggc aga cgg gtg gag ctt gcg ctt tgg      192
Val Ala Asp Val Glu Val Asp Gly Arg Arg Val Glu Leu Ala Leu Trp
             50             55             60

gat acg gct ggg cag gag gat tac gac agg cta cgg ccg tta tcg tac      240
Asp Thr Ala Gly Gln Glu Asp Tyr Asp Arg Leu Arg Pro Leu Ser Tyr
             65             70             75             80

cca gac tcc aat gtt gtg ttg atc tgc tac tcg att gac cta cca gac      288
Pro Asp Ser Asn Val Val Leu Ile Cys Tyr Ser Ile Asp Leu Pro Asp
             85             90             95

tcg ttg gag aac gtg atg gag aag tgg atc agc gag gtg cta tac ttc      336
Ser Leu Glu Asn Val Met Glu Lys Trp Ile Ser Glu Val Leu Tyr Phe
             100             105             110

tgc cag ggt gtt ccg atc atc ttg gtg ggg tgc aag gct gac ttg cgg      384
Cys Gln Gly Val Pro Ile Ile Leu Val Gly Cys Lys Ala Asp Leu Arg
             115             120             125

aac gat ccg caa gtg atc gag cag ttg aga cag cag gga cag cag cct      432
Asn Asp Pro Gln Val Ile Glu Gln Leu Arg Gln Gln Gly Gln Gln Pro
             130             135             140

gtc tcg cag gct cag gcg cag gag gta gcg gac cag atc ggc gcg gta      480
Val Ser Gln Ala Gln Ala Gln Glu Val Ala Asp Gln Ile Gly Ala Val
             145             150             155             160

gag tac att gag tgc tct gca aag acc ggc ttt ggt gtg cgc gag gtg      528
Glu Tyr Ile Glu Cys Ser Ala Lys Thr Gly Phe Gly Val Arg Glu Val
             165             170             175

ttt gag gcg gcc acg cgt gct tcc ttg atg ggg aaa caa ggc aag tct      576
Phe Glu Ala Ala Thr Arg Ala Ser Leu Met Gly Lys Gln Gly Lys Ser
             180             185             190

aag gcg aag tct gac aag aag aag aag aaa aag tgt gtg gtc ttg tag      624
Lys Ala Lys Ser Asp Lys Lys Lys Lys Lys Lys Cys Val Val Leu
             195             200             205

```

<210> SEQ ID NO 2

<211> LENGTH: 207

<212> TYPE: PRT

<213> ORGANISM: *Ashbya gossypii*

<400> SEQUENCE: 2

```

Met Ser Gln Gln Met His Asn Pro Ser Ile Arg Arg Lys Leu Val Ile
  1             5             10             15

Val Gly Asp Gly Ala Cys Gly Lys Thr Cys Leu Leu Ile Val Phe Ala
             20             25             30

Lys Gly Lys Phe Pro Gln Val Tyr Val Pro Thr Val Phe Asp Asn Tyr
             35             40             45

Val Ala Asp Val Glu Val Asp Gly Arg Arg Val Glu Leu Ala Leu Trp
             50             55             60

Asp Thr Ala Gly Gln Glu Asp Tyr Asp Arg Leu Arg Pro Leu Ser Tyr
             65             70             75             80

Pro Asp Ser Asn Val Val Leu Ile Cys Tyr Ser Ile Asp Leu Pro Asp
             85             90             95

```

-continued

Ser Leu Glu Asn Val Met Glu Lys Trp Ile Ser Glu Val Leu Tyr Phe
 100 105 110

Cys Gln Gly Val Pro Ile Ile Leu Val Gly Cys Lys Ala Asp Leu Arg
 115 120 125

Asn Asp Pro Gln Val Ile Glu Gln Leu Arg Gln Gln Gly Gln Gln Pro
 130 135 140

Val Ser Gln Ala Gln Ala Gln Glu Val Ala Asp Gln Ile Gly Ala Val
 145 150 155 160

Glu Tyr Ile Glu Cys Ser Ala Lys Thr Gly Phe Gly Val Arg Glu Val
 165 170 175

Phe Glu Ala Ala Thr Arg Ala Ser Leu Met Gly Lys Gln Gly Lys Ser
 180 185 190

Lys Ala Lys Ser Asp Lys Lys Lys Lys Lys Lys Cys Val Val Leu
 195 200 205

<210> SEQ ID NO 3
 <211> LENGTH: 675
 <212> TYPE: DNA
 <213> ORGANISM: *Ashbya gossypii*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(675)

<400> SEQUENCE: 3

atg cct ctg tgt ggg tcg agc tcg tcg tcg aag cat cct atc gag cgc 48
 Met Pro Leu Cys Gly Ser Ser Ser Ser Ser Ser Lys His Pro Ile Glu Arg
 1 5 10 15

aag atc gtc atc ctc gga gac ggt gct tgc ggg aag acg tcg ctg ttg 96
 Lys Ile Val Ile Leu Gly Asp Gly Ala Cys Gly Lys Thr Ser Leu Leu
 20 25 30

aac gtg ttc acg cga ggg tac ttt ccg aag gtg tac gag ccc acg gta 144
 Asn Val Phe Thr Arg Gly Tyr Phe Pro Lys Val Tyr Glu Pro Thr Val
 35 40 45

ttc gaa aac tac atc cat gac atc ttc gtg gac aac cag cac atc acg 192
 Phe Glu Asn Tyr Ile His Asp Ile Phe Val Asp Asn Gln His Ile Thr
 50 55 60

ctg agc ctg tgg gac act gct ggg cag gag gag ttt gac cgg ttg cga 240
 Leu Ser Leu Trp Asp Thr Ala Gly Gln Glu Glu Phe Asp Arg Leu Arg
 65 70 75 80

tcg ctg tcg tac tcg gac aca cac acg att atg ctg tgt ttc tcg gtg 288
 Ser Leu Ser Tyr Ser Asp Thr His Thr Ile Met Leu Cys Phe Ser Val
 85 90 95

gac tcg cgg gac tcg ctg gag aac gtc aag aac aag tgg gtg agc gaa 336
 Asp Ser Arg Asp Ser Leu Glu Asn Val Lys Asn Lys Trp Val Ser Glu
 100 105 110

att gcg gac cac tgc gag ggc gtg aag ctg gtg cta gtg gcg ctg aag 384
 Ile Ala Asp His Cys Glu Gly Val Lys Leu Val Leu Val Ala Leu Lys
 115 120 125

tgc gac ttg cgc agc agc gac gag tac ggc aac gag agc gcc atc acg 432
 Cys Asp Leu Arg Ser Ser Asp Glu Tyr Gly Asn Glu Ser Ala Ile Thr
 130 135 140

ccg ggg tcc atc cag aac cag aag tac aac ggc ggc ggc ggc aac ggg 480
 Pro Gly Ser Ile Gln Asn Gln Lys Tyr Asn Gly Gly Gly Gly Asn Gly
 145 150 155 160

ctg atc ccc tac gac gag ggg ctg gcg atg gcc aag cag att ggg gcg 528
 Leu Ile Pro Tyr Asp Glu Gly Leu Ala Met Ala Lys Gln Ile Gly Ala
 165 170 175

ctg cgc tat ctg gag tgc agc gcc aag atg aac cgt ggc gtg aac gag 576
 Leu Arg Tyr Leu Glu Cys Ser Ala Lys Met Asn Arg Gly Val Asn Glu
 180 185 190

-continued

gac gag cgc atc agc gcg acg ccg cgg agc tcg atc tcg tcg aat tca	144
Asp Glu Arg Ile Ser Ala Thr Pro Arg Ser Ser Ile Ser Ser Asn Ser	
35 40 45	
agc cct aat tcc aaa aat aat atg tcg cgt cat tcg cac tcc aat gga	192
Ser Pro Asn Ser Lys Asn Asn Met Ser Arg His Ser His Ser Asn Gly	
50 55 60	
tct gtt tac tca gat gaa aca aca ttg aag aca gcc caa acc cac tac	240
Ser Val Tyr Ser Asp Glu Thr Thr Leu Lys Thr Ala Gln Thr His Tyr	
65 70 75 80	
aca caa caa ggc caa cag gca aag ccg caa cag cac acg cag cag cag	288
Thr Gln Gln Gly Gln Ala Lys Pro Gln Gln His Thr Gln Gln Gln	
85 90 95	
cag cag cag cca cag acg ccg atg cag tta cag gtg ccg acg ggg caa	336
Gln Gln Gln Pro Gln Thr Pro Met Gln Leu Gln Val Pro Thr Gly Gln	
100 105 110	
gcg cac aag cgg acg ctg aca tgt gag gac atg aag gcg ggt gcg cgc	384
Ala His Lys Arg Thr Leu Thr Cys Glu Asp Met Lys Ala Gly Ala Arg	
115 120 125	
tgc gag gag cag gtg tcg ccc tgc tcg cag ccg gcg ggc tcg ccg gtg	432
Cys Glu Glu Gln Val Ser Pro Cys Ser Gln Pro Ala Gly Ser Pro Val	
130 135 140	
cga cgt gga ggc ggg ctg aac ggg gag acg tac gac ggg act gtg ttt	480
Arg Arg Gly Gly Gly Leu Asn Gly Glu Thr Tyr Asp Gly Thr Val Phe	
145 150 155 160	
cgg ctc ggg tgg gtg aac aag gcg cag ggc gca gcg ccg gcg cgc gag	528
Arg Leu Gly Trp Val Asn Lys Ala Gln Gly Ala Ala Pro Ala Arg Glu	
165 170 175	
ggg cga tac agc cac cag cca aca gcg tca ctg tct tcg atc gga tcg	576
Gly Arg Tyr Ser His Gln Pro Thr Ala Ser Leu Ser Ser Ile Gly Ser	
180 185 190	
gag cgg ccg cac ttc acg gga ggg ggg acg agc ggg tac cag tat gtc	624
Glu Arg Pro His Phe Thr Gly Gly Gly Thr Ser Gly Tyr Gln Tyr Val	
195 200 205	
gcg act gcg tac cgg ttg cac cgt gcg cag ctc aag ggc tgc atc ctg	672
Ala Thr Ala Tyr Arg Leu His Arg Ala Gln Leu Lys Gly Cys Ile Leu	
210 215 220	
aat ctg tac aag tcg ggc ctg acg aat gtg aag tac ttc gac ccg gcg	720
Asn Leu Tyr Lys Ser Gly Leu Thr Asn Val Lys Tyr Phe Asp Pro Ala	
225 230 235 240	
ctg gag ccg agc gct gcg gcg ctg cag atg cac cag gag cga cag gag	768
Leu Glu Pro Ser Ala Ala Ala Leu Gln Met His Gln Glu Arg Gln Glu	
245 250 255	
atg ccc ctc ctg cag ccg ccc ctc ccc tcc gag gct gtg ccg gcg cct	816
Met Pro Leu Leu Gln Pro Pro Leu Pro Ser Glu Ala Val Pro Ala Pro	
260 265 270	
tcg atc ctg gag gcg tcc atg gag agc ggc gag ctg cgg ctg gag tac	864
Ser Ile Leu Glu Ala Ser Met Glu Ser Gly Glu Leu Arg Leu Glu Tyr	
275 280 285	
ctg agc gag gcg tac cct cat ccg gac cta cag ctg gac aag aag gac	912
Leu Ser Glu Ala Tyr Pro His Pro Asp Leu Gln Leu Asp Lys Lys Asp	
290 295 300	
ggc aag atc ctt tcg ggg tcg ctg gag tcg ctg tgc cac gcc gtg ctg	960
Gly Lys Ile Leu Ser Gly Ser Leu Glu Ser Leu Cys His Ala Val Leu	
305 310 315 320	
ttc atg ccc acg act gac gcg aaa cgg gtc aca gac atc ttg ttg ctc	1008
Phe Met Pro Thr Thr Asp Ala Lys Arg Val Thr Asp Ile Leu Leu Leu	
325 330 335	
ctg ccg ctc ctg gac gac ttc acg cgt gtc ctc aac tac ttc aac ctg	1056
Leu Pro Leu Leu Asp Asp Phe Thr Arg Val Leu Asn Tyr Phe Asn Leu	

-continued

340		345		350		
ttc ggg aag gta ttt tcg aag cac cac ccg gcg ggc gcg gcg gga gcc						1104
Phe Gly Lys Val Phe Ser Lys His His Pro Ala Gly Ala Ala Gly Ala	355		360		365	
gat gac cta aat cag aac tac aac atc agc aac gag aca gac cgc caa						1152
Asp Asp Leu Asn Gln Asn Tyr Asn Ile Ser Asn Glu Thr Asp Arg Gln	370		375		380	
ttg acg ctg cgg cta gcc aca gtg gtc cag aca gtg ctg gac atg ttc						1200
Leu Thr Leu Arg Leu Ala Thr Val Val Gln Thr Val Leu Asp Met Phe	385		390		395	400
ccg ggc ttt ctg ctg gac gac aag att ttc cag tcc ctg gtg ata cta						1248
Pro Gly Phe Leu Leu Asp Asp Lys Ile Phe Gln Ser Leu Val Ile Leu		405		410		415
ctc gat acg att tcc ttc cac gat gaa gac acg tcg cag gag ctg aag						1296
Leu Asp Thr Ile Ser Phe His Asp Glu Asp Thr Ser Gln Glu Leu Lys		420		425		430
gtg gcg ata gcg gag aaa cag acg gta ctg gtc aag ctg acc ggc ttt						1344
Val Ala Ile Ala Glu Lys Gln Thr Val Leu Val Lys Leu Thr Gly Phe		435		440		445
gca aat gaa ccc atc cag tcc gcg aaa ctc gat gtt tta ata aag gtg						1392
Ala Asn Glu Pro Ile Gln Ser Ala Lys Leu Asp Val Leu Ile Lys Val		450		455		460
cag agc ttc ctg aaa ctt gat acc gag aag gtt gcc aac cag att cac						1440
Gln Ser Phe Leu Lys Leu Asp Thr Glu Lys Val Ala Asn Gln Ile His		465		470		475
aag atc aat cta acc ttt aat agg gta tgg agc cca caa gcc gat tat						1488
Lys Ile Asn Leu Thr Phe Asn Arg Val Trp Ser Pro Gln Ala Asp Tyr		485		490		495
tcc cta ctt tac gac tct caa tat aca caa aag cac gtg gaa cta aac						1536
Ser Leu Leu Tyr Asp Ser Gln Tyr Thr Gln Lys His Val Glu Leu Asn		500		505		510
cca ttg gta ttt ttc aac gat aaa aat gta cag tat ttg agt cgc tta						1584
Pro Leu Val Phe Phe Asn Asp Lys Asn Val Gln Tyr Leu Ser Arg Leu		515		520		525
atg gtg tct cat atc ttc tgc gaa gag acg gga ttt acg ccg aag aaa						1632
Met Val Ser His Ile Phe Cys Glu Glu Thr Gly Phe Thr Pro Lys Lys		530		535		540
cga gcg gag gtt ttg aca aaa tgg gtc caa ttg gga tgc aag ttt gag						1680
Arg Ala Glu Val Leu Thr Lys Trp Val Gln Leu Gly Cys Lys Phe Glu		545		550		555
cga ctt ggg gac atg gtc tca tgg ctt gca att gcg aca gta ata tgc						1728
Arg Leu Gly Asp Met Val Ser Trp Leu Ala Ile Ala Thr Val Ile Cys		565		570		575
tcc atc ccc gtt tta cgc ttg aca agg acg tgg caa tat gtg cct gac						1776
Ser Ile Pro Val Leu Arg Leu Thr Arg Thr Trp Gln Tyr Val Pro Asp		580		585		590
tct tac ttg aag ata att ttt aag gat tgg gta ccc acg att gtc cag						1824
Ser Tyr Leu Lys Ile Ile Phe Lys Asp Trp Val Pro Thr Ile Val Gln		595		600		605
ttg gat cgc agg caa atg tcc tcc aag tcg atg aac agt gtt ttc ata						1872
Leu Asp Arg Arg Gln Met Ser Ser Lys Ser Met Asn Ser Val Phe Ile		610		615		620
cta gcc cca cct aat tta aac gat gcc ttt gtg agg gac aat gtg atc						1920
Leu Ala Pro Pro Asn Leu Asn Asp Ala Phe Val Arg Asp Asn Val Ile		625		630		635
cct tac ttt ggc gac tta gtc att cac tcc gat gat cta ccc aga gac						1968
Pro Tyr Phe Gly Asp Leu Val Ile His Ser Asp Asp Leu Pro Arg Asp		645		650		655
agc aag tat aag tac ttg gag aaa aag ata cgc cgc aca aaa aat gcc						2016

-continued

Ser	Lys	Tyr	Lys	Tyr	Leu	Glu	Lys	Lys	Ile	Arg	Arg	Thr	Lys	Asn	Ala	
			660					665					670			
ttt	tac	aag	tgg	cag	cag	aga	cta	gac	cag	gca	ttt	gcg	cag	gat	aga	2064
Phe	Tyr	Lys	Trp	Gln	Gln	Arg	Leu	Asp	Gln	Ala	Phe	Ala	Gln	Asp	Arg	
		675					680					685				
gat	tct	gcc	agt	tcc	ttt	acg	gac	tcc	ttg	cat	ctt	gac	gag	gag	gaa	2112
Asp	Ser	Ala	Ser	Ser	Phe	Thr	Asp	Ser	Leu	His	Leu	Asp	Glu	Glu	Glu	
	690					695				700						
cat	gat	gtg	gca	gat	ttc	tat	cag	tat	tgg	agg	ttt	cac	atg	aat	ttg	2160
His	Asp	Val	Ala	Asp	Phe	Tyr	Gln	Tyr	Trp	Arg	Phe	His	Met	Asn	Leu	
705					710					715					720	
cca	cca	atg	aat	att	gaa	aca	att	atg	gaa	atg	agt	tta	aaa	atg	gaa	2208
Pro	Pro	Met	Asn	Ile	Glu	Thr	Ile	Met	Glu	Met	Ser	Leu	Lys	Met	Glu	
				725						730					735	
ccc	cct	tct	att	aat	caa	cag	act	tat	tcg	aag	aca	tac	tca	acg	aga	2256
Pro	Pro	Ser	Ile	Asn	Gln	Gln	Thr	Tyr	Ser	Lys	Thr	Tyr	Ser	Thr	Arg	
			740					745					750			
agt	gcg	ctc	atc	agt	ggg	gct	tat	ttg	ccg	acc	ttg	ttt	aca	aca	ttg	2304
Ser	Ala	Leu	Ile	Ser	Gly	Ala	Tyr	Leu	Pro	Thr	Leu	Phe	Thr	Thr	Leu	
		755				760						765				
tta	cca	tca	tat	tcc	ctg	ttt	cca	cag	gaa	cta	ctg	att	gca	gct	gca	2352
Leu	Pro	Ser	Tyr	Ser	Leu	Phe	Pro	Gln	Glu	Leu	Leu	Ile	Ala	Ala	Ala	
	770					775						780				
agc	acg	cca	tcc	acg	aaa	aat	aat	aac	tca	tct	caa	gcc	tct	aac	cgg	2400
Ser	Thr	Pro	Ser	Thr	Lys	Asn	Asn	Asn	Ser	Ser	Gln	Ala	Ser	Asn	Arg	
785					790					795					800	
atc	agc	caa	cta	tct	gtg	aat	tcg	aca	cct	cac	tca	aat	gcc	agt	tcg	2448
Ile	Ser	Gln	Leu	Ser	Val	Asn	Ser	Thr	Pro	His	Ser	Asn	Ala	Ser	Ser	
				805					810					815		
agt	tcc	gca	gcg	agc	gct	gtt	acc	gga	att	gat	aat	atc	gat	gtg	cca	2496
Ser	Ser	Ala	Ala	Ser	Ala	Val	Thr	Gly	Ile	Asp	Asn	Ile	Asp	Val	Pro	
			820					825						830		
att	aca	aag	gag	ata	tca	tcc	aag	tta	tca	aac	aaa	cag	gtt	tta	ctg	2544
Ile	Thr	Lys	Glu	Ile	Ser	Ser	Lys	Leu	Ser	Asn	Lys	Gln	Val	Leu	Leu	
		835					840					845				
aag	ttc	att	agg	gat	atg	ttc	aac	gta	gat	att	aac	gtt	ttc	cac	ata	2592
Lys	Phe	Ile	Arg	Asp	Met	Phe	Asn	Val	Asp	Ile	Asn	Val	Phe	His	Ile	
	850					855					860					
tct	gat	gat	gtt	att	ttc	aag	tcc	att	cg	gat	tac	gaa	gct	aaa	tcg	2640
Ser	Asp	Asp	Val	Ile	Phe	Lys	Ser	Ile	Arg	Asp	Tyr	Glu	Ala	Lys	Ser	
865					870					875					880	
agg	cct	act	agt	gtc	gtt	att	gaa	agt	ccc	aag	cgg	ttg	tcg	ctt	ctt	2688
Arg	Pro	Thr	Ser	Val	Val	Ile	Glu	Ser	Pro	Lys	Arg	Leu	Ser	Leu	Leu	
				885						890				895		
tct	tcg	gtc	tct	cct	gat	gta	tct	gct	gtc	agc	agt	gca	ttg	gaa	aat	2736
Ser	Ser	Val	Ser	Pro	Asp	Val	Ser	Ala	Val	Ser	Ser	Ala	Leu	Glu	Asn	
			900					905					910			
ttg	gat	ctg	ttc	aaa	aat	ttt	aac	tcc	agt	tct	gat	gat	atc	gcc	gaa	2784
Leu	Asp	Leu	Phe	Lys	Asn	Phe	Asn	Ser	Ser	Ser	Asp	Asp	Ile	Ala	Glu	
		915					920					925				
ttt	acc	gta	cag	gtg	gtg	ttg	aaa	tgt	gca	agc	ttg	gaa	aag	att	ttt	2832
Phe	Thr	Val	Gln	Val	Val	Leu	Lys	Cys	Ala	Ser	Leu	Glu	Lys	Ile	Phe	
		930					935				940					
gat	atc	ttg	gtc	tta	aca	agc	cgg	gtg	ttc	tcc	aac	ctc	gta	aca	act	2880
Asp	Ile	Leu	Val	Leu	Thr	Ser	Arg	Val	Phe	Ser	Asn	Leu	Val	Thr	Thr	
945					950					955					960	
aca	gat	ttg	gtt	tcc	tat	ttt	aat	agt	gaa	aag	gca	agg	cgg	gaa	aag	2928
Thr	Asp	Leu	Val	Ser	Tyr	Phe	Asn	Ser	Glu	Lys	Ala	Arg	Arg	Glu	Lys	
				965						970					975	

-continued

tca ggc gct caa cac aat ggt cag cac tct att ggt ttg tta gat ttt Ser Gly Ala Gln His Asn Gly Gln His Ser Ile Gly Leu Leu Asp Phe 980 985 990	2976
gca ttg att agc cta att atg gat aat gag ctc ttt gca gag acc ttt Ala Leu Ile Ser Leu Ile Met Asp Asn Glu Leu Phe Ala Glu Thr Phe 995 1000 1005	3024
ttt aac aac tac aaa agt ttt acg acg acg ttg tgc gta ctg gaa aac Phe Asn Asn Tyr Lys Ser Phe Thr Thr Thr Leu Cys Val Leu Glu Asn 1010 1015 1020	3072
ttg gca aag aga ttt atc ggt gcg aaa tcc tca gcc ata tct att agt Leu Ala Lys Arg Phe Ile Gly Ala Lys Ser Ser Ala Ile Ser Ile Ser 1025 1030 1035 1040	3120
cta atc aat aag tta cgg aat tct gaa tca tcc cgg cag ata cca cct Leu Ile Asn Lys Leu Arg Asn Ser Glu Ser Ser Arg Gln Ile Pro Pro 1045 1050 1055	3168
tct act acc tcc aac cag ttt tca gcg agt ggc atc ttt aag cca tca Ser Thr Thr Ser Asn Gln Phe Ser Ala Ser Gly Ile Phe Lys Pro Ser 1060 1065 1070	3216
tat gat gag ctt aaa ttc cct gtc tgg gat ctt aag gtc acc agc gtc Tyr Asp Glu Leu Lys Phe Pro Val Trp Asp Leu Lys Val Thr Ser Val 1075 1080 1085	3264
gaa ggc tgt ccg cta gac tac ctt gca aag att cag atc gga gta ttg Glu Gly Cys Pro Leu Asp Tyr Leu Ala Lys Ile Gln Ile Gly Val Leu 1090 1095 1100	3312
gaa tca cta tac cat ttg att aga gag cat tat gcg gac ttc acc gat Glu Ser Leu Tyr His Leu Ile Arg Glu His Tyr Ala Asp Phe Thr Asp 1105 1110 1115 1120	3360
gat ctc gct aac aac aaa acc ttt ctg gat att ctg aag atc att aac Asp Leu Ala Asn Asn Lys Thr Phe Leu Asp Ile Leu Lys Ile Ile Asn 1125 1130 1135	3408
cag gag gtt tat gat gag tgg gac aaa aga tta gat gac cta agg aat Gln Glu Val Tyr Asp Glu Trp Asp Lys Arg Leu Asp Asp Leu Arg Asn 1140 1145 1150	3456
aat aat aac agt agc cag aag agg aag aac agt tgc gat gat aat tct Asn Asn Asn Ser Ser Gln Lys Arg Lys Asn Ser Cys Asp Asp Asn Ser 1155 1160 1165	3504
agt gcc aag att act ttc cat gtt aat gat gct cga cct gaa aac tcc Ser Ala Lys Ile Thr Phe His Val Asn Asp Ala Arg Pro Glu Asn Ser 1170 1175 1180	3552
aat gag aat aag cgg ggt gcg gcg acg aat ttg ggg gat agc tcc tta Asn Glu Asn Lys Arg Gly Ala Ala Thr Asn Leu Gly Asp Ser Ser Leu 1185 1190 1195 1200	3600
gca gca ttg gaa aaa ctt caa tgt aca tta cag gat cta tac gtg aag Ala Ala Leu Glu Lys Leu Gln Cys Thr Leu Gln Asp Leu Tyr Val Lys 1205 1210 1215	3648
att aag tcc tca tat caa cgc caa tta tat cgt cca ttg ggc gtc aca Ile Lys Ser Ser Tyr Gln Arg Gln Leu Tyr Arg Pro Leu Gly Val Thr 1220 1225 1230	3696
aga aat tgc agg aaa gtt cac gat atg ctg tgc caa ttt cag ccg cag Arg Asn Cys Arg Lys Val His Asp Met Leu Cys Gln Phe Gln Pro Gln 1235 1240 1245	3744
act agt atg tcc gct ctt atc atg aat gga tct agt gac aca ctt gat Thr Ser Met Ser Ala Leu Ile Met Asn Gly Ser Ser Asp Thr Leu Asp 1250 1255 1260	3792
aag atg gtt acc gaa ttc cag gcc ctg aaa cac acc gat tat gat gat Lys Met Val Thr Glu Phe Gln Ala Leu Lys His Thr Asp Tyr Asp Asp 1265 1270 1275 1280	3840
att att aat tgg att tac aaa tta gat cat ttt att acc tcg aaa cta Ile Ile Asn Trp Ile Tyr Lys Leu Asp His Phe Ile Thr Ser Lys Leu 1285 1290 1295	3888

-continued

aag ctt gtt tcg aac caa gac tgg att caa gtg tcg caa att tta gag Lys Leu Val Ser Asn Gln Asp Trp Ile Gln Val Ser Gln Ile Leu Glu 1300 1305 1310	3936
tct ttg tcg aat gat tct ctt gtt gct ttg ttc aat tat cca ttg cat Ser Leu Ser Asn Asp Ser Leu Val Ala Leu Phe Asn Tyr Pro Leu His 1315 1320 1325	3984
gcg gaa tct aat aat gta att gca agt gga agt tct cag ttg gat gat Ala Glu Ser Asn Asn Val Ile Ala Ser Gly Ser Ser Gln Leu Asp Asp 1330 1335 1340	4032
ctt caa att ttg gat ata ttc acc tgg tta tca acg ctt gag agt ggt Leu Gln Ile Leu Asp Ile Phe Thr Trp Leu Ser Thr Leu Glu Ser Gly 1345 1350 1355 1360	4080
tca gca cac att att gat aag ttc cct gct agc gtt cag ttg ata gtc Ser Ala His Ile Ile Asp Lys Phe Pro Ala Ser Val Gln Leu Ile Val 1365 1370 1375	4128
aga ctg cat ttg tct ctg act aaa ttt ttt act gtg cat att gcc cat Arg Leu His Leu Ser Leu Thr Lys Phe Phe Thr Val His Ile Ala His 1380 1385 1390	4176
ctg cat tct acc tat gag gcc aga gtt aat act tgt tca ctt atc ttg Leu His Ser Thr Tyr Glu Ala Arg Val Asn Thr Cys Ser Leu Ile Leu 1395 1400 1405	4224
gag ata ctc aac ttt gtt cat gtt aag aat gcc aat gtt aat tta ttc Glu Ile Leu Asn Phe Val His Val Lys Asn Ala Asn Val Asn Leu Phe 1410 1415 1420	4272
cat tct gat gat gct ggg gag ggt tct atg gcc aca att tcg cca cat His Ser Asp Asp Ala Gly Glu Gly Ser Met Ala Thr Ile Ser Pro His 1425 1430 1435 1440	4320
gtc cca tct ttc atc gaa aca gcc ata gaa aac gcc atc ata agt cca Val Pro Ser Phe Ile Glu Thr Ala Ile Glu Asn Ala Ile Ile Ser Pro 1445 1450 1455	4368
gaa tcc cga ttt ttt gag gtt tca tgg aag caa gcc tat aag aca ata Glu Ser Arg Phe Phe Glu Val Ser Trp Lys Gln Ala Tyr Lys Thr Ile 1460 1465 1470	4416
tcc gag aaa gat gag aag ttg acg ttc att gga tct gtg ctt acc ggg Ser Glu Lys Asp Glu Lys Leu Thr Phe Ile Gly Ser Val Leu Thr Gly 1475 1480 1485	4464
tta gat aaa tcg acg gcg cac ttt ttg gat gcc gat aac agg cag cct Leu Asp Lys Ser Thr Ala His Phe Leu Asp Ala Asp Asn Arg Gln Pro 1490 1495 1500	4512
gtt agg ccc aag aat ttt tcg cct tgc ccg ggt tgg ttt atc tct cgt Val Arg Pro Lys Asn Phe Ser Pro Cys Pro Gly Trp Phe Ile Ser Arg 1505 1510 1515 1520	4560
ctg ttg gag atc act ggc cta gtt cct aac atg agc att gaa aat tcc Leu Leu Glu Ile Thr Gly Leu Val Pro Asn Met Ser Ile Glu Asn Ser 1525 1530 1535	4608
aaa atg atc aac ttt gac aaa agg cga ttc atc aat aac ata gtg ata Lys Met Ile Asn Phe Asp Lys Arg Arg Phe Ile Asn Asn Ile Val Ile 1540 1545 1550	4656
aac tat caa gac ttg att cca aat act gaa cag ctt ccg tct cat gat Asn Tyr Gln Asp Leu Ile Pro Asn Thr Glu Gln Leu Pro Ser His Asp 1555 1560 1565	4704
gat gaa aaa tcc gca cat caa ttt ggg tct atc ctt ttc cat tat ggc Asp Glu Lys Ser Ala His Gln Phe Gly Ser Ile Leu Phe His Tyr Gly 1570 1575 1580	4752
acc gag tca tcg att aag gca ttt aga aaa gct agt aag gag gct gct Thr Glu Ser Ser Ile Lys Ala Phe Arg Lys Ala Ser Lys Glu Ala Ala 1585 1590 1595 1600	4800
tca aat gag gca aga aaa ttg aag ttt caa gca atg ggc ttg ttc aat Ser Asn Glu Ala Arg Lys Leu Lys Phe Gln Ala Met Gly Leu Phe Asn	4848

-continued

															1605																1610																1615	
gat atc cta gtc act gaa gtc tac aag gtg cag aga gat caa aag aaa																																																4896
Asp Ile Leu Val Thr Glu Val Tyr Lys Val Gln Arg Asp Gln Lys Lys																																																
															1620																1625																1630	
cag gaa cag tta acc gta cag gaa cat gag gca aaa aga tca gtc ttg																																																4944
Gln Glu Gln Leu Thr Val Gln Glu His Glu Ala Lys Arg Ser Val Leu																																																
															1635																1640																1645	
att caa cac cca aac aaa gtg tct gtc tct tcg gct tca tct tca gtc																																																4992
Ile Gln His Pro Asn Lys Val Ser Val Ser Ser Ala Ser Ser Ser Val																																																
															1650																1655																1660	
tct ggg tct tcc agt ggc tct act gct aga act tct aat cct gct cat																																																5040
Ser Gly Ser Ser Ser Ser Gly Ser Thr Ala Arg Thr Ser Asn Pro Ala His																																																
															1665																1670																1675	1680
gct gct tac gcg tta aat atg gcc ggg tcc tta tca att tca gct gcc																																																5088
Ala Ala Tyr Ala Leu Asn Met Ala Gly Ser Leu Ser Ile Ser Ala Ala																																																
															1685																1690																1695	
aga cat ggt aga agc tct gtt tca tct agg agt tcg gta ata tca aat																																																5136
Arg His Gly Arg Ser Ser Val Ser Ser Arg Ser Ser Val Ile Ser Asn																																																
															1700																1705																1710	
acc gca act gct act tcc cca gca agt ggc gct tcc cca aac caa acc																																																5184
Thr Ala Thr Ala Thr Ser Pro Ala Ser Gly Ala Ser Pro Asn Gln Thr																																																
															1715																1720																1725	
agc acc tct cat cat ggg ggc atg ggt aaa aaa att ggt ggc ttt ttg																																																5232
Ser Thr Ser His His Gly Gly Met Gly Lys Lys Ile Gly Gly Phe Leu																																																
															1730																1735																1740	
agg agg cca ttc tcc atc agt gga ttt acc tcg tca tcc tct caa tat																																																5280
Arg Arg Pro Phe Ser Ile Ser Gly Phe Thr Ser Ser Ser Ser Gln Tyr																																																
															1745																1750																1755	1760
acc aca acg tca gtt gtg ctg tct ggc gtc cag gct aac ggc tct ata																																																5328
Thr Thr Thr Ser Val Leu Ser Gly Val Gln Ala Asn Gly Ser Ile																																																
															1765																1770																1775	
tcc cca tat gag cta ccc gaa ctc act tcc gaa ata caa gat aca aag																																																5376
Ser Pro Tyr Glu Leu Pro Glu Leu Thr Ser Glu Ile Gln Asp Thr Lys																																																
															1780																1785																1790	
atc gtc act gtc atc aag act ttt gag atc aaa tcg tgc atc caa atc																																																5424
Ile Val Thr Val Ile Lys Thr Phe Glu Ile Lys Ser Cys Ile Gln Ile																																																
															1795																1800																1805	
aac aac tac agg cag gat cct gat atg atg cat tgt ttt aag att gtt																																																5472
Asn Asn Tyr Arg Gln Asp Pro Asp Met Met His Cys Phe Lys Ile Val																																																
															1810																1815																1820	
atg gag gat ggt aca caa cat acc ctt caa tgt atg gac gac gct gat																																																5520
Met Glu Asp Gly Thr Gln His Thr Leu Gln Cys Met Asp Asp Ala Asp																																																
															1825																1830																1835	1840
atg cat gaa tgg atg aag gcc att aca ctc tct aaa aga tac tcc ttc																																																5568
Met His Glu Trp Met Lys Ala Ile Thr Leu Ser Lys Arg Tyr Ser Phe																																																
															1845																1850																1855	
cat tct aaa aga ttt aag ggt aaa aca tca aat aaa atc ttc ggt gta																																																5616
His Ser Lys Arg Phe Lys Gly Lys Thr Ser Asn Lys Ile Phe Gly Val																																																
															1860																1865																1870	
ccg gta gaa gac gtt tgc gaa aga gaa gga gcg tta ata ccc aat att																																																5664
Pro Val Glu Asp Val Cys Glu Arg Glu Gly Ala Leu Ile Pro Asn Ile																																																
															1875																1880																1885	
ata gtg aaa ttg ttg gat gaa atc gag ttg cgc ggg ctt gat gaa gtg																																																5712
Ile Val Lys Leu Leu Asp Glu Ile Glu Leu Arg Gly Leu Asp Glu Val																																																
															1890																1895																1900	
ggc cta tat agg gtg cct ggt tcc gtg ggc agc atc aat gca ctc aag																																																5760
Gly Leu Tyr Arg Val Pro Gly Ser Val Gly Ser Ile Asn Ala Leu Lys																																																
															1905																1910																1915	1920
aat gca ttt gac gat gag ggg gct gtt cac aac act ttt acg ctg gaa																																																5808

-continued

Asn	Ala	Phe	Asp	Asp	Glu	Gly	Ala	Val	His	Asn	Thr	Phe	Thr	Leu	Glu	
				1925					1930					1935		
gat	gac	cgt	tgg	ttt	gaa	ata	aat	act	att	gcc	ggg	tgt	ttt	aaa	cta	5856
Asp	Asp	Arg	Trp	Phe	Glu	Ile	Asn	Thr	Ile	Ala	Gly	Cys	Phe	Lys	Leu	
			1940					1945					1950			
tac	ctc	agg	gaa	ctt	cct	gaa	tct	ttg	ttc	aca	aat	gaa	aag	gtg	gac	5904
Tyr	Leu	Arg	Glu	Leu	Pro	Glu	Ser	Leu	Phe	Thr	Asn	Glu	Lys	Val	Asp	
		1955						1960					1965			
gag	ttc	gtt	aat	atc	atg	acc	gct	tac	aag	aac	cat	gag	gtt	gat	cta	5952
Glu	Phe	Val	Asn	Ile	Met	Thr	Ala	Tyr	Lys	Asn	His	Glu	Val	Asp	Leu	
		1970					1975				1980					
tcc	cag	ttc	cag	aat	ggt	ata	aag	acg	ctg	ctg	agt	acc	ttg	cct	gtt	6000
Ser	Gln	Phe	Gln	Asn	Gly	Ile	Lys	Thr	Leu	Leu	Ser	Thr	Leu	Pro	Val	
1985					1990					1995					2000	
ttc	aat	tac	cat	att	cta	aaa	cgg	ctg	ttc	ttg	cat	ctc	aac	cgc	gtt	6048
Phe	Asn	Tyr	His	Ile	Leu	Lys	Arg	Leu	Phe	Leu	His	Leu	Asn	Arg	Val	
			2005						2010					2015		
cac	cag	cat	gtt	gag	aat	aac	aga	atg	gat	gct	agc	aac	ttg	gca	att	6096
His	Gln	His	Val	Glu	Asn	Asn	Arg	Met	Asp	Ala	Ser	Asn	Leu	Ala	Ile	
			2020					2025					2030			
gtg	ttt	tcg	atg	tct	ttc	atc	aac	caa	gat	gat	ctt	gcc	agt	acg	atg	6144
Val	Phe	Ser	Met	Ser	Phe	Ile	Asn	Gln	Asp	Asp	Leu	Ala	Ser	Thr	Met	
		2035					2040					2045				
ggg	ccc	act	ttg	ggt	ttg	ctg	caa	atg	cta	cta	cag	cat	ctg	att	aga	6192
Gly	Pro	Thr	Leu	Gly	Leu	Leu	Gln	Met	Leu	Leu	Gln	His	Leu	Ile	Arg	
		2050				2055					2060					
aac	cca	gag	cat	tac	ttc	acc	tga									6216
Asn	Pro	Glu	His	Tyr	Phe	Thr										
2065					2070											

<210> SEQ ID NO 6
 <211> LENGTH: 2071
 <212> TYPE: PRT
 <213> ORGANISM: Ashbya gossypii

<400> SEQUENCE: 6

Met	Pro	Leu	Lys	Trp	Ala	Ala	Arg	Asn	Lys	Lys	Pro	Pro	Ser	Ala	Pro
1				5					10					15	
Gln	Ser	Cys	Ala	Ser	Lys	Pro	Ser	Ser	Ala	Ser	Gln	Ser	Ser	Cys	Val
			20					25					30		
Asp	Glu	Arg	Ile	Ser	Ala	Thr	Pro	Arg	Ser	Ser	Ile	Ser	Ser	Asn	Ser
		35					40					45			
Ser	Pro	Asn	Ser	Lys	Asn	Asn	Met	Ser	Arg	His	Ser	His	Ser	Asn	Gly
		50				55					60				
Ser	Val	Tyr	Ser	Asp	Glu	Thr	Thr	Leu	Lys	Thr	Ala	Gln	Thr	His	Tyr
		65			70					75					80
Thr	Gln	Gln	Gly	Gln	Gln	Ala	Lys	Pro	Gln	Gln	His	Thr	Gln	Gln	Gln
				85					90					95	
Gln	Gln	Gln	Pro	Gln	Thr	Pro	Met	Gln	Leu	Gln	Val	Pro	Thr	Gly	Gln
			100					105					110		
Ala	His	Lys	Arg	Thr	Leu	Thr	Cys	Glu	Asp	Met	Lys	Ala	Gly	Ala	Arg
		115					120					125			
Cys	Glu	Glu	Gln	Val	Ser	Pro	Cys	Ser	Gln	Pro	Ala	Gly	Ser	Pro	Val
		130				135					140				
Arg	Arg	Gly	Gly	Gly	Leu	Asn	Gly	Glu	Thr	Tyr	Asp	Gly	Thr	Val	Phe
		145			150					155					160
Arg	Leu	Gly	Trp	Val	Asn	Lys	Ala	Gln	Gly	Ala	Ala	Pro	Ala	Arg	Glu
				165					170						175

-continued

Gly Arg Tyr Ser His Gln Pro Thr Ala Ser Leu Ser Ser Ile Gly Ser
 180 185 190

Glu Arg Pro His Phe Thr Gly Gly Gly Thr Ser Gly Tyr Gln Tyr Val
 195 200 205

Ala Thr Ala Tyr Arg Leu His Arg Ala Gln Leu Lys Gly Cys Ile Leu
 210 215 220

Asn Leu Tyr Lys Ser Gly Leu Thr Asn Val Lys Tyr Phe Asp Pro Ala
 225 230 235 240

Leu Glu Pro Ser Ala Ala Ala Leu Gln Met His Gln Glu Arg Gln Glu
 245 250 255

Met Pro Leu Leu Gln Pro Pro Leu Pro Ser Glu Ala Val Pro Ala Pro
 260 265 270

Ser Ile Leu Glu Ala Ser Met Glu Ser Gly Glu Leu Arg Leu Glu Tyr
 275 280 285

Leu Ser Glu Ala Tyr Pro His Pro Asp Leu Gln Leu Asp Lys Lys Asp
 290 295 300

Gly Lys Ile Leu Ser Gly Ser Leu Glu Ser Leu Cys His Ala Val Leu
 305 310 315 320

Phe Met Pro Thr Thr Asp Ala Lys Arg Val Thr Asp Ile Leu Leu Leu
 325 330 335

Leu Pro Leu Leu Asp Asp Phe Thr Arg Val Leu Asn Tyr Phe Asn Leu
 340 345 350

Phe Gly Lys Val Phe Ser Lys His His Pro Ala Gly Ala Ala Gly Ala
 355 360 365

Asp Asp Leu Asn Gln Asn Tyr Asn Ile Ser Asn Glu Thr Asp Arg Gln
 370 375 380

Leu Thr Leu Arg Leu Ala Thr Val Val Gln Thr Val Leu Asp Met Phe
 385 390 395 400

Pro Gly Phe Leu Leu Asp Asp Lys Ile Phe Gln Ser Leu Val Ile Leu
 405 410 415

Leu Asp Thr Ile Ser Phe His Asp Glu Asp Thr Ser Gln Glu Leu Lys
 420 425 430

Val Ala Ile Ala Glu Lys Gln Thr Val Leu Val Lys Leu Thr Gly Phe
 435 440 445

Ala Asn Glu Pro Ile Gln Ser Ala Lys Leu Asp Val Leu Ile Lys Val
 450 455 460

Gln Ser Phe Leu Lys Leu Asp Thr Glu Lys Val Ala Asn Gln Ile His
 465 470 475 480

Lys Ile Asn Leu Thr Phe Asn Arg Val Trp Ser Pro Gln Ala Asp Tyr
 485 490 495

Ser Leu Leu Tyr Asp Ser Gln Tyr Thr Gln Lys His Val Glu Leu Asn
 500 505 510

Pro Leu Val Phe Phe Asn Asp Lys Asn Val Gln Tyr Leu Ser Arg Leu
 515 520 525

Met Val Ser His Ile Phe Cys Glu Glu Thr Gly Phe Thr Pro Lys Lys
 530 535 540

Arg Ala Glu Val Leu Thr Lys Trp Val Gln Leu Gly Cys Lys Phe Glu
 545 550 555 560

Arg Leu Gly Asp Met Val Ser Trp Leu Ala Ile Ala Thr Val Ile Cys
 565 570 575

Ser Ile Pro Val Leu Arg Leu Thr Arg Thr Trp Gln Tyr Val Pro Asp
 580 585 590

-continued

Ser	Tyr	Leu	Lys	Ile	Ile	Phe	Lys	Asp	Trp	Val	Pro	Thr	Ile	Val	Gln
		595					600					605			
Leu	Asp	Arg	Arg	Gln	Met	Ser	Ser	Lys	Ser	Met	Asn	Ser	Val	Phe	Ile
	610					615					620				
Leu	Ala	Pro	Pro	Asn	Leu	Asn	Asp	Ala	Phe	Val	Arg	Asp	Asn	Val	Ile
	625				630					635					640
Pro	Tyr	Phe	Gly	Asp	Leu	Val	Ile	His	Ser	Asp	Asp	Leu	Pro	Arg	Asp
				645					650					655	
Ser	Lys	Tyr	Lys	Tyr	Leu	Glu	Lys	Lys	Ile	Arg	Arg	Thr	Lys	Asn	Ala
			660					665					670		
Phe	Tyr	Lys	Trp	Gln	Gln	Arg	Leu	Asp	Gln	Ala	Phe	Ala	Gln	Asp	Arg
		675					680					685			
Asp	Ser	Ala	Ser	Ser	Phe	Thr	Asp	Ser	Leu	His	Leu	Asp	Glu	Glu	Glu
	690					695					700				
His	Asp	Val	Ala	Asp	Phe	Tyr	Gln	Tyr	Trp	Arg	Phe	His	Met	Asn	Leu
	705				710					715					720
Pro	Pro	Met	Asn	Ile	Glu	Thr	Ile	Met	Glu	Met	Ser	Leu	Lys	Met	Glu
				725					730					735	
Pro	Pro	Ser	Ile	Asn	Gln	Gln	Thr	Tyr	Ser	Lys	Thr	Tyr	Ser	Thr	Arg
			740					745						750	
Ser	Ala	Leu	Ile	Ser	Gly	Ala	Tyr	Leu	Pro	Thr	Leu	Phe	Thr	Thr	Leu
		755					760					765			
Leu	Pro	Ser	Tyr	Ser	Leu	Phe	Pro	Gln	Glu	Leu	Leu	Ile	Ala	Ala	Ala
	770					775						780			
Ser	Thr	Pro	Ser	Thr	Lys	Asn	Asn	Asn	Ser	Ser	Gln	Ala	Ser	Asn	Arg
	785				790					795					800
Ile	Ser	Gln	Leu	Ser	Val	Asn	Ser	Thr	Pro	His	Ser	Asn	Ala	Ser	Ser
				805					810						815
Ser	Ser	Ala	Ala	Ser	Ala	Val	Thr	Gly	Ile	Asp	Asn	Ile	Asp	Val	Pro
			820					825					830		
Ile	Thr	Lys	Glu	Ile	Ser	Ser	Lys	Leu	Ser	Asn	Lys	Gln	Val	Leu	Leu
		835					840					845			
Lys	Phe	Ile	Arg	Asp	Met	Phe	Asn	Val	Asp	Ile	Asn	Val	Phe	His	Ile
	850					855					860				
Ser	Asp	Asp	Val	Ile	Phe	Lys	Ser	Ile	Arg	Asp	Tyr	Glu	Ala	Lys	Ser
	865				870					875					880
Arg	Pro	Thr	Ser	Val	Val	Ile	Glu	Ser	Pro	Lys	Arg	Leu	Ser	Leu	Leu
				885					890					895	
Ser	Ser	Val	Ser	Pro	Asp	Val	Ser	Ala	Val	Ser	Ser	Ala	Leu	Glu	Asn
			900					905					910		
Leu	Asp	Leu	Phe	Lys	Asn	Phe	Asn	Ser	Ser	Ser	Asp	Asp	Ile	Ala	Glu
		915					920					925			
Phe	Thr	Val	Gln	Val	Val	Leu	Lys	Cys	Ala	Ser	Leu	Glu	Lys	Ile	Phe
						935					940				
Asp	Ile	Leu	Val	Leu	Thr	Ser	Arg	Val	Phe	Ser	Asn	Leu	Val	Thr	Thr
	945				950					955					960
Thr	Asp	Leu	Val	Ser	Tyr	Phe	Asn	Ser	Glu	Lys	Ala	Arg	Arg	Glu	Lys
				965					970					975	
Ser	Gly	Ala	Gln	His	Asn	Gly	Gln	His	Ser	Ile	Gly	Leu	Leu	Asp	Phe
			980					985						990	
Ala	Leu	Ile	Ser	Leu	Ile	Met	Asp	Asn	Glu	Leu	Phe	Ala	Glu	Thr	Phe
							1000					1005			
Phe	Asn	Asn	Tyr	Lys	Ser	Phe	Thr	Thr	Thr	Leu	Cys	Val	Leu	Glu	Asn

-continued

1010			1015			1020									
Leu	Ala	Lys	Arg	Phe	Ile	Gly	Ala	Lys	Ser	Ser	Ala	Ile	Ser	Ile	Ser
1025					1030						1035				1040
Leu	Ile	Asn	Lys	Leu	Arg	Asn	Ser	Glu	Ser	Ser	Arg	Gln	Ile	Pro	Pro
				1045						1050				1055	
Ser	Thr	Thr	Ser	Asn	Gln	Phe	Ser	Ala	Ser	Gly	Ile	Phe	Lys	Pro	Ser
			1060					1065					1070		
Tyr	Asp	Glu	Leu	Lys	Phe	Pro	Val	Trp	Asp	Leu	Lys	Val	Thr	Ser	Val
		1075						1080					1085		
Glu	Gly	Cys	Pro	Leu	Asp	Tyr	Leu	Ala	Lys	Ile	Gln	Ile	Gly	Val	Leu
		1090					1095				1100				
Glu	Ser	Leu	Tyr	His	Leu	Ile	Arg	Glu	His	Tyr	Ala	Asp	Phe	Thr	Asp
1105					1110						1115				1120
Asp	Leu	Ala	Asn	Asn	Lys	Thr	Phe	Leu	Asp	Ile	Leu	Lys	Ile	Ile	Asn
				1125						1130				1135	
Gln	Glu	Val	Tyr	Asp	Glu	Trp	Asp	Lys	Arg	Leu	Asp	Asp	Leu	Arg	Asn
			1140					1145					1150		
Asn	Asn	Asn	Ser	Ser	Gln	Lys	Arg	Lys	Asn	Ser	Cys	Asp	Asp	Asn	Ser
			1155					1160				1165			
Ser	Ala	Lys	Ile	Thr	Phe	His	Val	Asn	Asp	Ala	Arg	Pro	Glu	Asn	Ser
			1170					1175			1180				
Asn	Glu	Asn	Lys	Arg	Gly	Ala	Ala	Thr	Asn	Leu	Gly	Asp	Ser	Ser	Leu
1185					1190						1195				1200
Ala	Ala	Leu	Glu	Lys	Leu	Gln	Cys	Thr	Leu	Gln	Asp	Leu	Tyr	Val	Lys
				1205						1210				1215	
Ile	Lys	Ser	Ser	Tyr	Gln	Arg	Gln	Leu	Tyr	Arg	Pro	Leu	Gly	Val	Thr
			1220					1225					1230		
Arg	Asn	Cys	Arg	Lys	Val	His	Asp	Met	Leu	Cys	Gln	Phe	Gln	Pro	Gln
		1235						1240					1245		
Thr	Ser	Met	Ser	Ala	Leu	Ile	Met	Asn	Gly	Ser	Ser	Asp	Thr	Leu	Asp
		1250					1255				1260				
Lys	Met	Val	Thr	Glu	Phe	Gln	Ala	Leu	Lys	His	Thr	Asp	Tyr	Asp	Asp
1265					1270						1275				1280
Ile	Ile	Asn	Trp	Ile	Tyr	Lys	Leu	Asp	His	Phe	Ile	Thr	Ser	Lys	Leu
				1285						1290				1295	
Lys	Leu	Val	Ser	Asn	Gln	Asp	Trp	Ile	Gln	Val	Ser	Gln	Ile	Leu	Glu
			1300					1305					1310		
Ser	Leu	Ser	Asn	Asp	Ser	Leu	Val	Ala	Leu	Phe	Asn	Tyr	Pro	Leu	His
			1315					1320				1325			
Ala	Glu	Ser	Asn	Asn	Val	Ile	Ala	Ser	Gly	Ser	Ser	Gln	Leu	Asp	Asp
			1330				1335				1340				
Leu	Gln	Ile	Leu	Asp	Ile	Phe	Thr	Trp	Leu	Ser	Thr	Leu	Glu	Ser	Gly
1345					1350					1355					1360
Ser	Ala	His	Ile	Ile	Asp	Lys	Phe	Pro	Ala	Ser	Val	Gln	Leu	Ile	Val
				1365						1370				1375	
Arg	Leu	His	Leu	Ser	Leu	Thr	Lys	Phe	Phe	Thr	Val	His	Ile	Ala	His
			1380					1385					1390		
Leu	His	Ser	Thr	Tyr	Glu	Ala	Arg	Val	Asn	Thr	Cys	Ser	Leu	Ile	Leu
			1395					1400					1405		
Glu	Ile	Leu	Asn	Phe	Val	His	Val	Lys	Asn	Ala	Asn	Val	Asn	Leu	Phe
			1410				1415				1420				
His	Ser	Asp	Asp	Ala	Gly	Glu	Gly	Ser	Met	Ala	Thr	Ile	Ser	Pro	His
1425					1430						1435				1440

-continued

Val Pro Ser Phe Ile Glu Thr Ala Ile Glu Asn Ala Ile Ile Ser Pro
 1445 1450 1455
 Glu Ser Arg Phe Phe Glu Val Ser Trp Lys Gln Ala Tyr Lys Thr Ile
 1460 1465 1470
 Ser Glu Lys Asp Glu Lys Leu Thr Phe Ile Gly Ser Val Leu Thr Gly
 1475 1480 1485
 Leu Asp Lys Ser Thr Ala His Phe Leu Asp Ala Asp Asn Arg Gln Pro
 1490 1495 1500
 Val Arg Pro Lys Asn Phe Ser Pro Cys Pro Gly Trp Phe Ile Ser Arg
 1505 1510 1515 1520
 Leu Leu Glu Ile Thr Gly Leu Val Pro Asn Met Ser Ile Glu Asn Ser
 1525 1530 1535
 Lys Met Ile Asn Phe Asp Lys Arg Arg Phe Ile Asn Asn Ile Val Ile
 1540 1545 1550
 Asn Tyr Gln Asp Leu Ile Pro Asn Thr Glu Gln Leu Pro Ser His Asp
 1555 1560 1565
 Asp Glu Lys Ser Ala His Gln Phe Gly Ser Ile Leu Phe His Tyr Gly
 1570 1575 1580
 Thr Glu Ser Ser Ile Lys Ala Phe Arg Lys Ala Ser Lys Glu Ala Ala
 1585 1590 1595 1600
 Ser Asn Glu Ala Arg Lys Leu Lys Phe Gln Ala Met Gly Leu Phe Asn
 1605 1610 1615
 Asp Ile Leu Val Thr Glu Val Tyr Lys Val Gln Arg Asp Gln Lys Lys
 1620 1625 1630
 Gln Glu Gln Leu Thr Val Gln Glu His Glu Ala Lys Arg Ser Val Leu
 1635 1640 1645
 Ile Gln His Pro Asn Lys Val Ser Val Ser Ser Ala Ser Ser Ser Val
 1650 1655 1660
 Ser Gly Ser Ser Ser Gly Ser Thr Ala Arg Thr Ser Asn Pro Ala His
 1665 1670 1675 1680
 Ala Ala Tyr Ala Leu Asn Met Ala Gly Ser Leu Ser Ile Ser Ala Ala
 1685 1690 1695
 Arg His Gly Arg Ser Ser Val Ser Ser Arg Ser Ser Val Ile Ser Asn
 1700 1705 1710
 Thr Ala Thr Ala Thr Ser Pro Ala Ser Gly Ala Ser Pro Asn Gln Thr
 1715 1720 1725
 Ser Thr Ser His His Gly Gly Met Gly Lys Lys Ile Gly Gly Phe Leu
 1730 1735 1740
 Arg Arg Pro Phe Ser Ile Ser Gly Phe Thr Ser Ser Ser Ser Gln Tyr
 1745 1750 1755 1760
 Thr Thr Thr Ser Val Val Leu Ser Gly Val Gln Ala Asn Gly Ser Ile
 1765 1770 1775
 Ser Pro Tyr Glu Leu Pro Glu Leu Thr Ser Glu Ile Gln Asp Thr Lys
 1780 1785 1790
 Ile Val Thr Val Ile Lys Thr Phe Glu Ile Lys Ser Cys Ile Gln Ile
 1795 1800 1805
 Asn Asn Tyr Arg Gln Asp Pro Asp Met Met His Cys Phe Lys Ile Val
 1810 1815 1820
 Met Glu Asp Gly Thr Gln His Thr Leu Gln Cys Met Asp Asp Ala Asp
 1825 1830 1835 1840
 Met His Glu Trp Met Lys Ala Ile Thr Leu Ser Lys Arg Tyr Ser Phe
 1845 1850 1855

-continued

His Ser Lys Arg Phe Lys Gly Lys Thr Ser Asn Lys Ile Phe Gly Val
 1860 1865 1870
 Pro Val Glu Asp Val Cys Glu Arg Glu Gly Ala Leu Ile Pro Asn Ile
 1875 1880 1885
 Ile Val Lys Leu Leu Asp Glu Ile Glu Leu Arg Gly Leu Asp Glu Val
 1890 1895 1900
 Gly Leu Tyr Arg Val Pro Gly Ser Val Gly Ser Ile Asn Ala Leu Lys
 1905 1910 1915 1920
 Asn Ala Phe Asp Asp Glu Gly Ala Val His Asn Thr Phe Thr Leu Glu
 1925 1930 1935
 Asp Asp Arg Trp Phe Glu Ile Asn Thr Ile Ala Gly Cys Phe Lys Leu
 1940 1945 1950
 Tyr Leu Arg Glu Leu Pro Glu Ser Leu Phe Thr Asn Glu Lys Val Asp
 1955 1960 1965
 Glu Phe Val Asn Ile Met Thr Ala Tyr Lys Asn His Glu Val Asp Leu
 1970 1975 1980
 Ser Gln Phe Gln Asn Gly Ile Lys Thr Leu Leu Ser Thr Leu Pro Val
 1985 1990 1995 2000
 Phe Asn Tyr His Ile Leu Lys Arg Leu Phe Leu His Leu Asn Arg Val
 2005 2010 2015
 His Gln His Val Glu Asn Asn Arg Met Asp Ala Ser Asn Leu Ala Ile
 2020 2025 2030
 Val Phe Ser Met Ser Phe Ile Asn Gln Asp Asp Leu Ala Ser Thr Met
 2035 2040 2045
 Gly Pro Thr Leu Gly Leu Leu Gln Met Leu Leu Gln His Leu Ile Arg
 2050 2055 2060
 Asn Pro Glu His Tyr Phe Thr
 2065 2070

<210> SEQ ID NO 7
 <211> LENGTH: 3042
 <212> TYPE: DNA
 <213> ORGANISM: Ashbya gossypii
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(3042)

<400> SEQUENCE: 7

atg gga gac ggg tca gac gca gaa cgc agc ggg ggg aca agc tcg tcc 48
 Met Gly Asp Gly Ser Asp Ala Glu Arg Ser Gly Gly Thr Ser Ser Ser
 1 5 10 15
 tca gca ttg gaa ctt ctt gcg cag tat gag cag cac att atg gag cgg 96
 Ser Ala Leu Glu Leu Leu Ala Gln Tyr Glu Gln His Ile Met Glu Arg
 20 25 30
 ggg agg acg ttg gag gcg att gaa ggg cac ggc ggg gag cgg ctg ggg 144
 Gly Arg Thr Leu Glu Ala Ile Glu Gly His Gly Gly Glu Arg Leu Gly
 35 40 45
 cca acg tac gag gag ctt gtg gag gag aac gtg cag ctc cgg cgg gag 192
 Pro Thr Tyr Glu Glu Leu Val Glu Glu Asn Val Gln Leu Arg Arg Glu
 50 55 60
 ctg cag ggg cag cgg gag gaa ata gaa cac ctc cgc aaa acg att tct 240
 Leu Gln Gly Gln Arg Glu Glu Ile Glu His Leu Arg Lys Thr Ile Ser
 65 70 75 80
 ctg ctt gcg tcg ggg cgg agc ggc gcg acg gtg gtc gag cag cag gtg 288
 Leu Leu Ala Ser Gly Arg Ser Gly Ala Thr Val Val Glu Gln Gln Val
 85 90 95
 cgt cct gag cct tcg ccg tcc gta cga gag ctg gcg ctg ccg ccg cgg 336
 Arg Pro Glu Pro Ser Pro Ser Val Arg Glu Leu Ala Leu Pro Pro Arg

-continued

100			105			110										
tcc	gcg	gac	cgg	cga	aag	aac	acc	aaa	aac	ctg	agt	ctc	gcc	ccg	gtg	384
Ser	Ala	Asp	Arg	Arg	Lys	Asn	Thr	Lys	Asn	Leu	Ser	Leu	Ala	Pro	Val	
		115					120					125				
ggc	cac	gag	gtg	ccg	tcg	acc	gac	cgg	ctg	cgt	gtc	tcg	ccg	cag	gag	432
Gly	His	Glu	Val	Pro	Ser	Thr	Asp	Arg	Leu	Arg	Val	Ser	Pro	Gln	Glu	
	130					135				140						
gcc	acg	agc	ggg	gca	cag	cag	gtg	ccc	ttg	cta	acc	tct	tcg	aag	tcc	480
Ala	Thr	Ser	Gly	Ala	Gln	Gln	Val	Pro	Leu	Leu	Thr	Ser	Ser	Lys	Ser	
145					150					155					160	
gcc	gag	att	ctg	gtg	tcg	aaa	tct	ccg	gat	gaa	gac	cgc	cac	ttg	atg	528
Ala	Glu	Ile	Leu	Val	Ser	Lys	Ser	Pro	Asp	Glu	Asp	Arg	His	Leu	Met	
			165						170					175		
tcg	cct	agg	aag	aca	att	tca	cgg	tcc	agt	tcg	tca	tat	tcg	aat	acg	576
Ser	Pro	Arg	Lys	Thr	Ile	Ser	Arg	Ser	Ser	Ser	Ser	Tyr	Ser	Asn	Thr	
			180					185						190		
cta	ggc	agc	cct	gca	act	tcc	gtt	ctg	tat	aag	aac	tct	cgg	ata	tca	624
Leu	Gly	Ser	Pro	Ala	Thr	Ser	Val	Leu	Tyr	Lys	Asn	Ser	Arg	Ile	Ser	
		195					200					205				
att	act	tct	ccg	tgc	aag	tct	aac	tct	acg	agc	aaa	gct	gcg	tct	gtg	672
Ile	Thr	Ser	Pro	Cys	Lys	Ser	Asn	Ser	Thr	Ser	Lys	Ala	Ala	Ser	Val	
	210					215					220					
ttg	agt	cta	cca	gaa	aat	aac	acg	tcc	acc	gag	aat	gcg	ccg	cat	tca	720
Leu	Ser	Leu	Pro	Glu	Asn	Asn	Thr	Ser	Thr	Glu	Asn	Ala	Pro	His	Ser	
225					230					235					240	
cca	cac	aga	ata	gac	aac	gaa	ttg	gac	ttg	ctc	acc	gtg	gag	cct	caa	768
Pro	His	Arg	Ile	Asp	Asn	Glu	Leu	Asp	Leu	Leu	Thr	Val	Glu	Pro	Gln	
			245					250						255		
gat	gga	agc	agg	tac	gat	aca	gag	aga	gca	ggt	ggt	ccg	ggg	cca	ttg	816
Asp	Gly	Ser	Arg	Tyr	Asp	Thr	Glu	Arg	Ala	Gly	Gly	Pro	Gly	Pro	Leu	
		260						265					270			
tcg	cct	gag	agc	ata	gtg	tac	agt	gat	tcg	gac	ttg	caa	gag	cat	caa	864
Ser	Pro	Glu	Ser	Ile	Val	Tyr	Ser	Asp	Ser	Asp	Leu	Gln	Glu	His	Gln	
		275					280					285				
cct	tct	gat	ctg	tca	tct	acc	act	agg	acg	gat	tta	ggc	aaa	ttc	aga	912
Pro	Ser	Asp	Leu	Ser	Ser	Thr	Thr	Arg	Thr	Asp	Leu	Gly	Lys	Phe	Arg	
		290				295					300					
gat	atg	gtg	gat	act	acc	ttc	aat	gca	gaa	gac	aac	cct	acg	ggt	tca	960
Asp	Met	Val	Asp	Thr	Thr	Phe	Asn	Ala	Glu	Asp	Asn	Pro	Thr	Gly	Ser	
305					310					315					320	
cga	gac	aag	gag	act	gga	acg	gaa	atg	gag	atc	gct	acg	cta	caa	aat	1008
Arg	Asp	Lys	Glu	Thr	Gly	Thr	Glu	Met	Glu	Ile	Ala	Thr	Leu	Gln	Asn	
				325					330					335		
acg	ccc	agc	aga	caa	cat	gaa	tcg	agt	ttg	gta	aca	agt	cca	caa	gct	1056
Thr	Pro	Ser	Arg	Gln	His	Glu	Ser	Ser	Leu	Val	Thr	Ser	Pro	Gln	Ala	
			340					345					350			
tct	agg	tca	tcg	att	aca	acg	cca	gtc	gtg	gat	cct	act	aat	acg	agc	1104
Ser	Arg	Ser	Ser	Ile	Thr	Thr	Pro	Val	Val	Asp	Pro	Thr	Asn	Thr	Ser	
		355					360					365				
gaa	cct	tct	tcg	ctt	tca	gca	gcg	aag	ttt	gga	agt	atg	tct	acc	gct	1152
Glu	Pro	Ser	Ser	Leu	Ser	Ala	Ala	Lys	Phe	Gly	Ser	Met	Ser	Thr	Ala	
	370					375				380						
aca	tcc	tcg	aac	aaa	agg	tcc	aag	ggc	atg	ggc	act	cct	tcc	gtg	gaa	1200
Thr	Ser	Ser	Asn	Lys	Arg	Ser	Lys	Gly	Met	Gly	Thr	Pro	Ser	Val	Glu	
385					390					395					400	
cat	tca	gca	aag	tca	tac	tcg	cag	cat	tct	ggt	agc	ccc	cac	tct	aac	1248
His	Ser	Ala	Lys	Ser	Tyr	Ser	Gln	His	Ser	Gly	Ser	Pro	His	Ser	Asn	
				405					410					415		
tct	cac	cag	tcc	aag	aaa	gca	gat	att	ccc	tta	ttt	gta	cag	cca	gag	1296

-continued

Ser	His	Gln	Ser	Lys	Lys	Ala	Asp	Ile	Pro	Leu	Phe	Val	Gln	Pro	Glu	
			420					425					430			
gag	tta	ggt	acg	atc	agg	att	gag	gtc	att	agt	aca	ttg	tat	cat	gag	1344
Glu	Leu	Gly	Thr	Ile	Arg	Ile	Glu	Val	Ile	Ser	Thr	Leu	Tyr	His	Glu	
			435				440					445				
cct	gga	aac	gca	gcc	agc	att	ctc	ttt	agt	gtt	gtt	gat	aag	aag	tct	1392
Pro	Gly	Asn	Ala	Ala	Ser	Ile	Leu	Phe	Ser	Val	Val	Asp	Lys	Lys	Ser	
	450					455					460					
tcc	aag	gag	atg	ttc	aaa	ttt	gct	aaa	act	ttt	acc	cgc	att	gca	gag	1440
Ser	Lys	Glu	Met	Phe	Lys	Phe	Ala	Lys	Thr	Phe	Thr	Arg	Ile	Ala	Glu	
	465				470					475					480	
ttc	gat	acc	ttt	atc	aga	aac	aat	atg	gaa	tct	tta	gcc	gtc	ccc	ccc	1488
Phe	Asp	Thr	Phe	Ile	Arg	Asn	Asn	Met	Glu	Ser	Leu	Ala	Val	Pro	Pro	
				485					490						495	
ctt	ccc	gac	aag	cac	atg	ttt	gct	tcg	aac	gtg	cca	gta	aag	gta	gac	1536
Leu	Pro	Asp	Lys	His	Met	Phe	Ala	Ser	Asn	Val	Pro	Val	Lys	Val	Asp	
			500					505					510			
agt	agg	aga	gaa	aag	ctt	aat	gac	tac	ttt	gct	agt	ttg	ttg	tat	cta	1584
Ser	Arg	Arg	Glu	Lys	Leu	Asn	Asp	Tyr	Phe	Ala	Ser	Leu	Leu	Tyr	Leu	
		515					520					525				
tcc	cca	tta	ccc	ttt	aat	cca	gca	ttg	aag	tta	gcg	caa	ttc	att	agc	1632
Ser	Pro	Leu	Pro	Phe	Asn	Pro	Ala	Leu	Lys	Leu	Ala	Gln	Phe	Ile	Ser	
	530					535					540					
aca	gac	cct	gtt	atg	aac	cct	ata	act	ggc	gaa	ttt	gct	aaa	gag	ggc	1680
Thr	Asp	Pro	Val	Met	Asn	Pro	Ile	Thr	Gly	Glu	Phe	Ala	Lys	Glu	Gly	
	545				550					555					560	
atg	cta	cta	gtc	cgt	aaa	tct	aaa	acc	ttg	ggt	agt	act	act	acg	tg	1728
Met	Leu	Leu	Val	Arg	Lys	Ser	Lys	Thr	Leu	Gly	Ser	Thr	Thr	Thr	Trp	
				565					570					575		
cgt	att	agg	tac	tgc	aca	gtt	gag	ggc	tct	ata	atg	cat	ctc	cat	gac	1776
Arg	Ile	Arg	Tyr	Cys	Thr	Val	Glu	Gly	Ser	Ile	Met	His	Leu	His	Asp	
			580					585					590			
cat	atg	att	gat	act	gat	acg	atc	aaa	ttg	acg	cat	tct	acg	att	gaa	1824
His	Met	Ile	Asp	Thr	Asp	Thr	Ile	Lys	Leu	Thr	His	Ser	Thr	Ile	Glu	
		595					600					605				
ctt	cag	gca	aac	ctc	ccg	gat	gat	aag	tat	ggg	acc	aag	aat	gga	ttc	1872
Leu	Gln	Ala	Asn	Leu	Pro	Asp	Asp	Lys	Tyr	Gly	Thr	Lys	Asn	Gly	Phe	
	610					615					620					
ata	ctt	aat	gaa	cac	aaa	aag	agt	ggt	ctt	tca	agc	tct	aca	aag	tac	1920
Ile	Leu	Asn	Glu	His	Lys	Lys	Ser	Gly	Leu	Ser	Ser	Ser	Thr	Lys	Tyr	
	625				630					635					640	
tat	ttt	tgc	gct	gaa	acg	cca	aaa	gaa	cgt	gaa	caa	tg	ata	agc	gta	1968
Tyr	Phe	Cys	Ala	Glu	Thr	Pro	Lys	Glu	Arg	Glu	Gln	Trp	Ile	Ser	Val	
				645					650					655		
ttg	acc	act	ctc	tgc	gat	ggc	cca	ggt	ggt	aca	gca	gcc	att	cca	tcc	2016
Leu	Thr	Thr	Leu	Cys	Asp	Gly	Pro	Gly	Gly	Thr	Ala	Ala	Ile	Pro	Ser	
			660					665					670			
att	aat	agc	aag	tct	gaa	gcg	tct	agt	tta	ttc	gag	caa	aca	agc	att	2064
Ile	Asn	Ser	Lys	Ser	Glu	Ala	Ser	Ser	Leu	Phe	Glu	Gln	Thr	Ser	Ile	
		675					680					685				
agc	gac	tct	agt	tat	ctt	gga	cca	att	gct	aat	ctc	gag	gca	atg	gat	2112
Ser	Asp	Ser	Ser	Tyr	Leu	Gly	Pro	Ile	Ala	Asn	Leu	Glu	Ala	Met	Asp	
		690				695					700					
gca	act	tct	ccg	aca	aga	cca	aat	gat	cca	aac	ccg	gtc	tcc	tta	aca	2160
Ala	Thr	Ser	Pro	Thr	Arg	Pro	Asn	Asp	Pro	Asn	Pro	Val	Ser	Leu	Thr	
	705				710						715				720	
tct	gaa	gaa	gag	aaa	gag	gtc	aag	aga	cga	cgt	atg	aag	tca	ttc	ttc	2208
Ser	Glu	Glu	Glu	Lys	Glu	Val	Lys	Arg	Arg	Arg	Met	Lys	Ser	Phe	Phe	
				725					730					735		

-continued

cct ttc aag aag tta gct act aca cct acc ccc tac gct gct gga aac	2256
Pro Phe Lys Lys Leu Ala Thr Thr Pro Thr Pro Tyr Ala Ala Gly Asn	
740 745 750	
gac aat gct tct ata ttt tcg caa gat gat gat agc cct gtg aat gct	2304
Asp Asn Ala Ser Ile Phe Ser Gln Asp Asp Asp Ser Pro Val Asn Ala	
755 760 765	
aca aat gaa agt ggt att tca aga tca ctc cag tcc atg aat tta caa	2352
Thr Asn Glu Ser Gly Ile Ser Arg Ser Leu Gln Ser Met Asn Leu Gln	
770 775 780	
gca cag tat aac gcg gta ttt gga gcg gac ttg aga tcc tgt tta caa	2400
Ala Gln Tyr Asn Ala Val Phe Gly Ala Asp Leu Arg Ser Cys Leu Gln	
785 790 795 800	
cta agt tcg cat ccc tac cag gga aaa tat gaa ata cca agt gtt gta	2448
Leu Ser Ser His Pro Tyr Gln Gly Lys Tyr Glu Ile Pro Ser Val Val	
805 810 815	
ttc cga acg cta gaa ttc ttg tac aaa aac cgc ggc att cag gaa gaa	2496
Phe Arg Thr Leu Glu Phe Leu Tyr Lys Asn Arg Gly Ile Gln Glu Glu	
820 825 830	
ggt ata ttt agg tta agc gga tcc agt tct ctc ata aaa tct ttg cag	2544
Gly Ile Phe Arg Leu Ser Gly Ser Ser Ser Leu Ile Lys Ser Leu Gln	
835 840 845	
gag caa ttt gac aaa gaa tat gac gtg gat ttg tgc aat tac aac gat	2592
Glu Gln Phe Asp Lys Glu Tyr Asp Val Asp Leu Cys Asn Tyr Asn Asp	
850 855 860	
aaa gtt tct gtc aca cca gga aac gaa aat cag ggc ggt ctc tac gtc	2640
Lys Val Ser Val Thr Pro Gly Asn Glu Asn Gln Gly Gly Leu Tyr Val	
865 870 875 880	
gat gtg aat acc gtt tca ggt tta tta aaa cta tac cta aga aag ctt	2688
Asp Val Asn Thr Val Ser Gly Leu Leu Lys Leu Tyr Leu Arg Lys Leu	
885 890 895	
cct cat atg atc ttt ggg gat gct gca tat atg gat ttt aag aga atc	2736
Pro His Met Ile Phe Gly Asp Ala Ala Tyr Met Asp Phe Lys Arg Ile	
900 905 910	
gtg gaa aga aac gga gat gat agc aaa cta ata gca ctc gag ttc agg	2784
Val Glu Arg Asn Gly Asp Asp Ser Lys Leu Ile Ala Leu Glu Phe Arg	
915 920 925	
gca ttg gtt aat tcc gga cga att gcc aaa gaa tat gtc gcc tta atg	2832
Ala Leu Val Asn Ser Gly Arg Ile Ala Lys Glu Tyr Val Ala Leu Met	
930 935 940	
tat gca ttg ttc gag tta ttg gtg aag atc acc gag aac agc aaa tat	2880
Tyr Ala Leu Phe Glu Leu Leu Val Lys Ile Thr Glu Asn Ser Lys Tyr	
945 950 955 960	
aac aag atg aat ctg cgg aat ttg tgt atc gta ttt tcg cca acg ttg	2928
Asn Lys Met Asn Leu Arg Asn Leu Cys Ile Val Phe Ser Pro Thr Leu	
965 970 975	
aac ata ccc gtg aat ata cta cat ccg ttt atc act gac ttt ggc tgt	2976
Asn Ile Pro Val Asn Ile Leu His Pro Phe Ile Thr Asp Phe Gly Cys	
980 985 990	
ata ttc caa gat aag gcg ccg atg gag aac gga cca ccg gtc aac ata	3024
Ile Phe Gln Asp Lys Ala Pro Met Glu Asn Gly Pro Pro Val Asn Ile	
995 1000 1005	
cac atc ccg caa att tag	3042
His Ile Pro Gln Ile	
1010	

<210> SEQ ID NO 8

<211> LENGTH: 1013

<212> TYPE: PRT

<213> ORGANISM: Ashbya gossypii

<400> SEQUENCE: 8

-continued

Met Gly Asp Gly Ser Asp Ala Glu Arg Ser Gly Gly Thr Ser Ser Ser
 1 5 10 15
 Ser Ala Leu Glu Leu Leu Ala Gln Tyr Glu Gln His Ile Met Glu Arg
 20 25 30
 Gly Arg Thr Leu Glu Ala Ile Glu Gly His Gly Gly Glu Arg Leu Gly
 35 40 45
 Pro Thr Tyr Glu Glu Leu Val Glu Glu Asn Val Gln Leu Arg Arg Glu
 50 55 60
 Leu Gln Gly Gln Arg Glu Glu Ile Glu His Leu Arg Lys Thr Ile Ser
 65 70 75 80
 Leu Leu Ala Ser Gly Arg Ser Gly Ala Thr Val Val Glu Gln Gln Val
 85 90 95
 Arg Pro Glu Pro Ser Pro Ser Val Arg Glu Leu Ala Leu Pro Pro Arg
 100 105 110
 Ser Ala Asp Arg Arg Lys Asn Thr Lys Asn Leu Ser Leu Ala Pro Val
 115 120 125
 Gly His Glu Val Pro Ser Thr Asp Arg Leu Arg Val Ser Pro Gln Glu
 130 135 140
 Ala Thr Ser Gly Ala Gln Gln Val Pro Leu Leu Thr Ser Ser Lys Ser
 145 150 155 160
 Ala Glu Ile Leu Val Ser Lys Ser Pro Asp Glu Asp Arg His Leu Met
 165 170 175
 Ser Pro Arg Lys Thr Ile Ser Arg Ser Ser Ser Tyr Ser Asn Thr
 180 185 190
 Leu Gly Ser Pro Ala Thr Ser Val Leu Tyr Lys Asn Ser Arg Ile Ser
 195 200 205
 Ile Thr Ser Pro Cys Lys Ser Asn Ser Thr Ser Lys Ala Ala Ser Val
 210 215 220
 Leu Ser Leu Pro Glu Asn Asn Thr Ser Thr Glu Asn Ala Pro His Ser
 225 230 235 240
 Pro His Arg Ile Asp Asn Glu Leu Asp Leu Leu Thr Val Glu Pro Gln
 245 250 255
 Asp Gly Ser Arg Tyr Asp Thr Glu Arg Ala Gly Gly Pro Gly Pro Leu
 260 265 270
 Ser Pro Glu Ser Ile Val Tyr Ser Asp Ser Asp Leu Gln Glu His Gln
 275 280 285
 Pro Ser Asp Leu Ser Ser Thr Thr Arg Thr Asp Leu Gly Lys Phe Arg
 290 295 300
 Asp Met Val Asp Thr Thr Phe Asn Ala Glu Asp Asn Pro Thr Gly Ser
 305 310 315 320
 Arg Asp Lys Glu Thr Gly Thr Glu Met Glu Ile Ala Thr Leu Gln Asn
 325 330 335
 Thr Pro Ser Arg Gln His Glu Ser Ser Leu Val Thr Ser Pro Gln Ala
 340 345 350
 Ser Arg Ser Ser Ile Thr Thr Pro Val Val Asp Pro Thr Asn Thr Ser
 355 360 365
 Glu Pro Ser Ser Leu Ser Ala Ala Lys Phe Gly Ser Met Ser Thr Ala
 370 375 380
 Thr Ser Ser Asn Lys Arg Ser Lys Gly Met Gly Thr Pro Ser Val Glu
 385 390 395 400
 His Ser Ala Lys Ser Tyr Ser Gln His Ser Gly Ser Pro His Ser Asn
 405 410 415

-continued

835	840	845	
Glu Gln Phe Asp Lys Glu Tyr Asp Val Asp Leu Cys Asn Tyr Asn Asp			
850	855	860	
Lys Val Ser Val Thr Pro Gly Asn Glu Asn Gln Gly Gly Leu Tyr Val			
865	870	875	880
Asp Val Asn Thr Val Ser Gly Leu Leu Lys Leu Tyr Leu Arg Lys Leu			
885	890	895	
Pro His Met Ile Phe Gly Asp Ala Ala Tyr Met Asp Phe Lys Arg Ile			
900	905	910	
Val Glu Arg Asn Gly Asp Asp Ser Lys Leu Ile Ala Leu Glu Phe Arg			
915	920	925	
Ala Leu Val Asn Ser Gly Arg Ile Ala Lys Glu Tyr Val Ala Leu Met			
930	935	940	
Tyr Ala Leu Phe Glu Leu Leu Val Lys Ile Thr Glu Asn Ser Lys Tyr			
945	950	955	960
Asn Lys Met Asn Leu Arg Asn Leu Cys Ile Val Phe Ser Pro Thr Leu			
965	970	975	
Asn Ile Pro Val Asn Ile Leu His Pro Phe Ile Thr Asp Phe Gly Cys			
980	985	990	
Ile Phe Gln Asp Lys Ala Pro Met Glu Asn Gly Pro Pro Val Asn Ile			
995	1000	1005	
His Ile Pro Gln Ile			
1010			

<210> SEQ ID NO 9
 <211> LENGTH: 530
 <212> TYPE: DNA
 <213> ORGANISM: Ashbya gossypii
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(528)

<400> SEQUENCE: 9

cag gcc atg cat gaa ggg tta aat ata ata aaa att gac aac tgg cta	48
Gln Ala Met His Glu Gly Leu Asn Ile Ile Lys Ile Asp Asn Trp Leu	
1 5 10 15	
gaa gtg ata ccg cag ttg ata tcc cga att cac cag cct aac caa acc	96
Glu Val Ile Pro Gln Leu Ile Ser Arg Ile His Gln Pro Asn Gln Thr	
20 25 30	
gtg agt aga aca tta tta tct ctc tta tct gac ctc ggc aag gct cat	144
Val Ser Arg Thr Leu Leu Ser Leu Leu Ser Asp Leu Gly Lys Ala His	
35 40 45	
cct cag gct ctc gtc ttc cct cta aca gtt gct ata aaa tct gaa tct	192
Pro Gln Ala Leu Val Phe Pro Leu Thr Val Ala Ile Lys Ser Glu Ser	
50 55 60	
gta tct agg cag aga gct gct ttg tct att atg gag aag atg cgt atg	240
Val Ser Arg Gln Arg Ala Ala Leu Ser Ile Met Glu Lys Met Arg Met	
65 70 75 80	
cat agt tct aat ctg gtt gaa cag gca gaa ctg gtt agc aat gag ctc	288
His Ser Ser Asn Leu Val Glu Gln Ala Glu Leu Val Ser Asn Glu Leu	
85 90 95	
att cgt att gct gtg ctg tgg cat gag cta tgg tat gaa ggt ctg gag	336
Ile Arg Ile Ala Val Leu Trp His Glu Leu Trp Tyr Glu Gly Leu Glu	
100 105 110	
gac gcg agt aga cag ttt ctc gga gag cat aat acg gaa aag atg ttc	384
Asp Ala Ser Arg Gln Phe Leu Gly Glu His Asn Thr Glu Lys Met Phe	
115 120 125	
gct act ttg gaa cca ctg cat gaa atg ttg aag agg gga cct gag act	432

-continued

Ala Thr Leu Glu Pro Leu His Glu Met Leu Lys Arg Gly Pro Glu Thr	
130	135 140
cta cgg gag ata tca ttc cag aat tca ttt ggt aga gac ctg aat gac	480
Leu Arg Glu Ile Ser Phe Gln Asn Ser Phe Gly Arg Asp Leu Asn Asp	
145	150 155 160
gca tat gaa tgg gtc atg aac tat aag agg aca cag gat atc agt aat	528
Ala Tyr Glu Trp Val Met Asn Tyr Lys Arg Thr Gln Asp Ile Ser Asn	
	165 170 175
tt	530

<210> SEQ ID NO 10
 <211> LENGTH: 176
 <212> TYPE: PRT
 <213> ORGANISM: Ashbya gossypii

<400> SEQUENCE: 10

Gln Ala Met His Glu Gly Leu Asn Ile Ile Lys Ile Asp Asn Trp Leu	
1	5 10 15
Glu Val Ile Pro Gln Leu Ile Ser Arg Ile His Gln Pro Asn Gln Thr	
	20 25 30
Val Ser Arg Thr Leu Leu Ser Leu Leu Ser Asp Leu Gly Lys Ala His	
	35 40 45
Pro Gln Ala Leu Val Phe Pro Leu Thr Val Ala Ile Lys Ser Glu Ser	
	50 55 60
Val Ser Arg Gln Arg Ala Ala Leu Ser Ile Met Glu Lys Met Arg Met	
	65 70 75 80
His Ser Ser Asn Leu Val Glu Gln Ala Glu Leu Val Ser Asn Glu Leu	
	85 90 95
Ile Arg Ile Ala Val Leu Trp His Glu Leu Trp Tyr Glu Gly Leu Glu	
	100 105 110
Asp Ala Ser Arg Gln Phe Leu Gly Glu His Asn Thr Glu Lys Met Phe	
	115 120 125
Ala Thr Leu Glu Pro Leu His Glu Met Leu Lys Arg Gly Pro Glu Thr	
	130 135 140
Leu Arg Glu Ile Ser Phe Gln Asn Ser Phe Gly Arg Asp Leu Asn Asp	
	145 150 155 160
Ala Tyr Glu Trp Val Met Asn Tyr Lys Arg Thr Gln Asp Ile Ser Asn	
	165 170 175

<210> SEQ ID NO 11
 <211> LENGTH: 402
 <212> TYPE: DNA
 <213> ORGANISM: Ashbya gossypii
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(402)

<400> SEQUENCE: 11

gtg gac act tca ggc atg tcg aga gag acg cta cgg tac tac gaa ttt	48
Val Asp Thr Ser Gly Met Ser Arg Glu Thr Leu Arg Tyr Tyr Glu Phe	
1	5 10 15
ctc tgt aga gtt gga gag gca aaa cgt tgg att gag gat gtg atc ggc	96
Leu Cys Arg Val Gly Glu Ala Lys Arg Trp Ile Glu Asp Val Ile Gly	
	20 25 30
gag acg ata cct gga gaa ctc gag ttg gca gct ggt aat tca atg cgc	144
Glu Thr Ile Pro Gly Glu Leu Glu Leu Ala Ala Gly Asn Ser Met Arg	
	35 40 45
gac ggc tat ttt ttg gcg aag gtc act caa acg att aaa cct gat ctt	192
Asp Gly Tyr Phe Leu Ala Lys Val Thr Gln Thr Ile Lys Pro Asp Leu	

-continued

50	55	60	
gca cct aca att gta cct cct ggt cgg ttg cag ttc aag cat aca cag			240
Ala Pro Thr Ile Val Pro Pro Gly Arg Leu Gln Phe Lys His Thr Gln			
65	70	75	80
aat att aat gct ttt ttt tcg ctg atg gat ttg gta ggc gta ccg gac			288
Asn Ile Asn Ala Phe Phe Ser Leu Met Asp Leu Val Gly Val Pro Asp			
	85	90	95
cta ttt cga ttt gaa ctg acc gac cta tac gag aag aaa gac gtt cca			336
Leu Phe Arg Phe Glu Leu Thr Asp Leu Tyr Glu Lys Lys Asp Val Pro			
	100	105	110
aaa gtt ttt gag act tta cat gca gtc gcg aac att ctc aat agt agg			384
Lys Val Phe Glu Thr Leu His Ala Val Ala Asn Ile Leu Asn Ser Arg			
	115	120	125
ttc ccc ggc gag att cct			402
Phe Pro Gly Glu Ile Pro			
	130		

<210> SEQ ID NO 12
 <211> LENGTH: 134
 <212> TYPE: PRT
 <213> ORGANISM: *Ashbya gossypii*

<400> SEQUENCE: 12

Val Asp Thr Ser Gly Met Ser Arg Glu Thr Leu Arg Tyr Tyr Glu Phe			
1	5	10	15
Leu Cys Arg Val Gly Glu Ala Lys Arg Trp Ile Glu Asp Val Ile Gly			
	20	25	30
Glu Thr Ile Pro Gly Glu Leu Glu Leu Ala Ala Gly Asn Ser Met Arg			
	35	40	45
Asp Gly Tyr Phe Leu Ala Lys Val Thr Gln Thr Ile Lys Pro Asp Leu			
	50	55	60
Ala Pro Thr Ile Val Pro Pro Gly Arg Leu Gln Phe Lys His Thr Gln			
	65	70	75
Asn Ile Asn Ala Phe Phe Ser Leu Met Asp Leu Val Gly Val Pro Asp			
	85	90	95
Leu Phe Arg Phe Glu Leu Thr Asp Leu Tyr Glu Lys Lys Asp Val Pro			
	100	105	110
Lys Val Phe Glu Thr Leu His Ala Val Ala Asn Ile Leu Asn Ser Arg			
	115	120	125
Phe Pro Gly Glu Ile Pro			
	130		

<210> SEQ ID NO 13
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 13

gctagggata acagggtaat 20

<210> SEQ ID NO 14
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 14

-continued

aggcatgcaa gcttagatct	20
<p><210> SEQ ID NO 15 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:Primer</p>	
<400> SEQUENCE: 15	
gtttagtctg accatctcat ctg	23
<p><210> SEQ ID NO 16 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:Primer</p>	
<400> SEQUENCE: 16	
tcgcagaccg ataccaggat c	21
<p><210> SEQ ID NO 17 <211> LENGTH: 65 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:Primer</p>	
<400> SEQUENCE: 17	
aggaccacta gctcgttgcg ctgcaatata ataataagaa cgagagctag ggataacagg	60
gtaat	65
<p><210> SEQ ID NO 18 <211> LENGTH: 65 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:Primer</p>	
<400> SEQUENCE: 18	
aagtattcaa tcaactatgt gagtagtttc ttgtaggcag tctccaggca tgcaagctta	60
gatct	65
<p><210> SEQ ID NO 19 <211> LENGTH: 65 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:Primer</p>	
<400> SEQUENCE: 19	
ctggcatcag aggaagctcc caccaccaag ctctacaaac acaaggctag ggataacagg	60
gtaat	65
<p><210> SEQ ID NO 20 <211> LENGTH: 65 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:Primer</p>	
<400> SEQUENCE: 20	
attatattag tatagtctaa agttgcaggc agtgggtatt aaagtaggca tgcaagctta	60

-continued

gatct 65

<210> SEQ ID NO 21
 <211> LENGTH: 65
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 21

acttgcgtac tctttcgcgt gtcgctcagc caccgaacaa cgcaggctag ggataacagg 60

gtaat 65

<210> SEQ ID NO 22
 <211> LENGTH: 65
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 22

ttaaagaatg ataaagaacc aaaaacacca cgagcttgca taacaaggca tgcaagctta 60

gatct 65

<210> SEQ ID NO 23
 <211> LENGTH: 65
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 23

gtgctgtca gcgagcatct aatcaagctg caaggcgccg gaaatgctag ggataacagg 60

gtaat 65

<210> SEQ ID NO 24
 <211> LENGTH: 65
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 24

ttatcacata tttctaagtt aatagatatt tttacttagt atgaaaggca tgcaagctta 60

gatct 65

<210> SEQ ID NO 25
 <211> LENGTH: 65
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:Primer

<400> SEQUENCE: 25

gagagagacg ctacggtact acgaatttct ctgtagagtt ggagagctag ggataacagg 60

gtaat 65

<210> SEQ ID NO 26
 <211> LENGTH: 65
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

```

<223> OTHER INFORMATION: Description of Artificial Sequence:Primer
<400> SEQUENCE: 26
tactattgag aatggtcgcg actgcatgta aagtctcaaa aacttaggca tgcaagctta    60
gatct                                           65

<210> SEQ ID NO 27
<211> LENGTH: 65
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:Primer
<400> SEQUENCE: 27
aaatataata aaaattgaca actggctaga agtgataccg cagttgctag ggataacagg    60
gtaat                                           65

<210> SEQ ID NO 28
<211> LENGTH: 65
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:Primer
<400> SEQUENCE: 28
cctcttatag ttcatgaccc attcatatgc gtcattcagg tctctaggca tgcaagctta    60
gatct                                           65

```

What is claimed is:

1. An isolated nucleotide sequence consisting essentially of SEQ ID NO: 1.
2. The isolated nucleotide sequence of claim 1, wherein the nucleotide sequence is SEQ ID NO: 1.
3. The isolated nucleotide sequence of claim 1, wherein the nucleotide sequence is a fungal nucleotide sequence.
4. The isolated nucleotide sequence of claim 3, wherein the fungus is *Ashbya gossypii*.

5. The isolated nucleotide sequence of claim 1, wherein the nucleotide sequence encodes an amino acid sequence consisting essentially of SEQ ID NO: 2.

6. An isolated nucleotide sequence encoding an amino acid sequence according to SEQ ID NO: 2.

* * * * *